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Abstract
Stromal interaction molecule 1 (STIM1) is an endo/sarcoplasmic reticulum (ER/SR)
calcium (Ca2+) sensor that activates store-operated Ca2+ entry (SOCE) following Ca2+
depletion. SOCE-induced elevation of cytosolic Ca2+ stimulates the calcineurin/nuclear
factor of activated T cells (NFAT) pathway, which upregulates pro-hypertrophic gene
transcription. Nitric oxide (NO) regulates protein functions by S-nitrosylation, but how
NO regulates SOCE in inhibiting cardiac hypertrophy is unclear. I hypothesize that NO
stabilizes and inhibits STIM1 via S-nitrosylation and mitigates cardiomyocyte
hypertrophy. STIM1 residues Cys49 and Cys56 were susceptible to S-nitrosylation by Snitrosoglutathione (GSNO) and sodium nitroprusside (SNP), resulting in luminal Ca2+
sensing domain stabilization, reduced oligomerization, enhanced rigidification, and
suppressed hydrophobic exposure upon Ca2+-depletion. Phenotypically, STIM1 siRNA,
SOCE channel blocker BTP2, GSNO or ectopic nNOS expression inhibited
phenylephrine-induced cardiomyocyte hypertrophy. Collectively, my data show that
STIM1 S-nitrosylation inhibits SOCE and cardiomyocyte hypertrophy thereby providing
new insight into how STIM1 modification contributes to Ca2+ signaling in
cardiomyocytes.

Keywords
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cardiomyocyte, hypertrophy, store-operated calcium entry, nuclear magnetic resonance
spectroscopy, stability, oligomerization

ii

Co-Authorship Statement
Dr. Qingping Feng and Dr. Peter B. Stathopulos supervised and contributed to the design
of all the experiments. Sharon Lu greatly helped with the collection of data associated
with the neonatal rat cardiomyocyte experiments.

iii

Acknowledgments
I would like to express my most sincere gratitude towards my supervisors Dr. Qingping
Feng and Dr. Peter B. Stathopulos for their continuous support, understanding and
patience. I really appreciate their assistance with not just the design of my experiments
but also with my scholarship applications and this Master’s thesis. Their expertise and
guidance have allowed me to improve my practical laboratory skills, critical thinking
skills as well as my ability to effectively write for academic journals and orally
communicate to broad audiences. I could not have imagined having a better team of
supervisors to mentor me for my Master’s study. I would also like to thank my advisory
committee members Dr. Wei-Yang Lu and Dr. John DiGuglielmo for their valuable
feedback, encouragement and assistance with my research project.
A very special thanks to our lab manager Sharon Lu for her guidance and assistance with
all my experiments using neonatal rat cardiomyocytes. The countless weekends and
holidays that she sacrificed to help me with my experiment are vital for the successful
completion of my project.
I would also like to thank my past and present lab members in Dr. Feng and Dr.
Stathopulos’ lab: Yoo Jung Choi, Sam Lee, Jessica Blom, Anish Engineer, Tana Saiyin,
Naveed Siddiqui, Steve Chung, Edward Kim and Allen Feng. Their presence and the
stimulating discussions we had made my time in the lab an extremely pleasant
experience. A huge thanks to our lab volunteer Benjamin Harvey for his assistance with
some of the rate limiting steps in my project which has allowed me to spend more time to
focus on other areas of my research and efficiently conduct my experiments.
I must also thank my family and friends for the support they have provided me
throughout my life and their consoling words that get me through my toughest days.
Their encouragement and trust in me have given me the confidence to believe in myself
and pursue my dreams.

iv

Table of Contents
Abstract ................................................................................................................................ i
Co-Authorship Statement ................................................................................................... ii
Acknowledgments ............................................................................................................. iii
Table of Contents ............................................................................................................... iv
List of Tables ................................................................................................................... viii
List of Figures .................................................................................................................... ix
Chapter 1 Introduction ........................................................................................................ 1
1.1 Overall goals ........................................................................................................... 1
1.2 Calcium ................................................................................................................... 2
1.2.1

General functions of Ca2+ ........................................................................... 2

1.2.2

Ca2+ function in the immune system........................................................... 3

1.2.3

Intracellular Ca2+ compartmentalization ..................................................... 3

1.2.4

Ca2+ signalling impairments in the heart .................................................... 4

1.3 SOCE and CRAC channels .................................................................................... 5
1.4 Stromal interaction molecule (STIM) and Orai ...................................................... 9
1.4.1

STIM domain organization ......................................................................... 9

1.4.2

Orai domain organization ......................................................................... 14

1.4.3

STIM1 and Orai1 function........................................................................ 15

1.5 Cardiac hypertrophy ............................................................................................. 17
1.5.1

Physiological and pathological hypertrophy............................................. 17

1.5.2

Intracellular signalling pathway ............................................................... 18

1.5.3

Role of Ca2+ and SOCE ............................................................................ 19

1.6 Nitric oxide synthase ............................................................................................ 20

v

1.6.1

iNOS ......................................................................................................... 20

1.6.2

eNOS......................................................................................................... 20

1.6.3

nNOS ........................................................................................................ 21

1.7 S-Nitrosylation ...................................................................................................... 22
1.7.1

Mechanism of S-nitrosylation ................................................................... 22

1.7.2

Effect of S-nitrosylation on different proteins .......................................... 22

1.7.3

S-nitrosylation and cardiac function ......................................................... 23

1.8 Summary and Rationale ........................................................................................ 25
1.9 Hypothesis and aims ............................................................................................. 26
Chapter 2 Methods ............................................................................................................ 28
2.1 Generation of STIM1 constructs and mutants ...................................................... 28
2.2 Protein expression and purification ...................................................................... 33
2.2.1

pET-28a STIM1 23-213 wildtype and mutants ........................................ 33

2.2.2

pGEX-4T1 STIM1 24-57 ......................................................................... 37

2.2.3

pET-28a STIM1 58-201 (EF-SAM) ......................................................... 41

2.3 S-Nitrosylation of STIM1 ..................................................................................... 44
2.4 Far-UV circular dichroism (CD) spectroscopy..................................................... 44
2.5 Ca2+ binding .......................................................................................................... 45
2.6 8-Anilinonaphthalene-1-sulfonic acid (ANS) binding ......................................... 46
2.7 Dynamic light scattering (DLS)............................................................................ 47
2.8 Solution nuclear magnetic resonance (NMR) spectroscopy ................................. 47
2.8.1

STIM1 24-57 backbone assignment and structure ................................... 47

2.8.2

Paramagnetic relaxation enhancement (PRE) spectroscopy ..................... 49

2.9 Urea Denaturation ................................................................................................. 51
2.10 Cardiomyocyte Culture ........................................................................................ 52

vi

2.10.1 Cardiomyocyte isolation and culture ........................................................ 52
2.10.2 Experimental treatments ........................................................................... 52
2.10.3 Cardiomyocyte staining and imaging ....................................................... 52
2.11 Statistical analysis ................................................................................................ 53
Chapter 3 Results .............................................................................................................. 54
3.1 The α-helicity of STIM1 23-213 is attenuated upon Ca2+ depletion. ................... 54
3.2 S-Nitrosylation increases the thermal stability of STIM1 23-213 wildtype protein.
.............................................................................................................................. 56
3.3 S-Nitrosylation decreases the structural change of STIM1 23-213 upon Ca2+
binding. ................................................................................................................. 60
3.4 S-Nitrosylation decreases the level of solvent-exposed hydrophobicity of wildtype
STIM1 23-213. ..................................................................................................... 62
3.5 Wildtype STIM1 23-213 undergoes S-nitrosylation mediated de-oligomerization.
.............................................................................................................................. 65
3.6 S-Nitrosylation of STIM1 24-57 peptide causes residue specific chemical shift
changes. ................................................................................................................ 67
3.7 S-Nitrosylation induces thermodynamic stabilization of STIM1 23-213. ............ 72
3.8 STIM1 24-57 peptide transiently interacts with STIM1 58-201 (EF-SAM core) at
residues Trp121 and Lys122. ................................................................................ 75
3.9 STIM1 23-213 Trp121Glu/Lys122Glu double mutant does not de-oligomerize
following GSNO treatment. .................................................................................. 79
3.10 STIM1 siRNA and BTP2 blockade of Orai1 channel activity decreased PEinduced hypertrophy ............................................................................................. 81
3.11 GSNO and adenoviral nNOS inhibits PE-induced hypertrophy........................... 81
Chapter 4 Discussion ........................................................................................................ 86
4.1 Summary ............................................................................................................... 86
4.2 S-Nitrosylation ...................................................................................................... 87
4.3 S-Nitrosylation of luminal STIM1 region increases protein stability. .................. 88
4.4 S-Nitrosylation of luminal STIM1 suppresses Ca2+-dependent conformational

vii

changes and oligomerization. ............................................................................... 90
4.5 STIM1 24-57 peptide interacts with STIM1 58-201 (EF-SAM domain) at residues
Trp121 and Lys122 to mediate S-nitrosylation-induced stabilization of STIM1. 92
4.6 Inhibition of the SOCE pathway prevents the development of PE-induced
cardiomyocyte hypertrophy. ................................................................................. 93
4.7 Future directions and limitations .......................................................................... 95
4.8 Conclusions........................................................................................................... 96
References....................................................................................................................... 100
Curriculum Vitae ............................................................................................................ 120

viii

List of Tables
Table 2.1. Oligonucleotide primers used in the research described in this thesis. (SigmaAldrich, St. Louis, MO) .................................................................................................... 31
Table 2.2. PCR amplification parameters on LifeECO (Bioer). ....................................... 32
Table 3.1 Apparent denaturation midpoint (Tm) of STIM1 23-213 wildtype, double and
single mutants under conditions with or without Ca2+ and/or S-nitrosylation. ................. 57
Table 3.2 Thermodynamic stability parameters for STIM1 23-213 wildtype and
Cys49Ser/Cys56Ser double mutant protein under Ca2+-loaded and -depleted conditions.
........................................................................................................................................... 73
Table 4.1. Summary of the effect of S-nitrosylation on various properties associated with
STIM1 activation. ............................................................................................................. 97

ix

List of Figures
Figure 1.1. Schematic diagram of agonist-induced cardiomyocyte hypertrophy mediated
by SOCE…………………………………………………………………………………..8
Figure 1.2. Domain architecture and primary sequence alignment of STIM protein……12
Figure 1.3. Depiction of the mechanism through which cysteine residues are Snitrosylated……………………………………………………………………………….24
Figure 2.1. Coomassie Blue R-250 staining of STIM1 23-213 on a 15 % (w/v) SDSPAGE gel………………………………………………………………………………...35
Figure 2.2. Size exclusion chromatography elution profile of STIM1 23-213………...36
Figure 2.3. Size exclusion chromatography elution profile of STIM1 24-57 containing the
Tyr insert………………………………………………………..………………………..39
Figure 2.4. Transformed mass spectrum of STIM1 24-57 peptide……………………....40
Figure 2.5. Anion exchange chromatography elution profile of wildtype EF-SAM
protein……………………………………………………………………………………43
Figure 2.6. 1H-15N-Heteronuclear single quantum coherence (HSQC) spectra of STIM1
24-57……………………………………………………………………………………..50
Figure 3.1. Far-UV CD spectra of wildtype STIM1 23-213……………………………..55
Figure 3.2. S-nitrosylation induced thermal stabilization of STIM1 23-213…………….58
Figure 3.3. S-nitrosylation did not induce thermal stabilization of STIM1 23-213 Cys
mutants…………………………………………………………………………………59
Figure 3.4. Ca2+ binding to STIM1 23-213 wildtype protein with and without NO
donors…………………………………………………………………………………….61

x

Figure 3.5. Extrinsic fluorescence of ANS in the presence of STIM1 23-213…….…….64
Figure 3.6. Dynamic light scattering (DLS) analysis of STIM1 23-213………….……..66
Figure 3.7. Solution NMR assessment of structural changes caused by S-nitrosylation of
STIM1 24-57……………………………………………………………………………..69
Figure 3.8. NMR chemical shift perturbation (CSP) of STIM1 24-57 before and after Snitrosylation……………………………………………………………………………...70
Figure 3.9. Model-free order parameter (S2) predicted from the random coil index
(RCI)……………………………………………………………………………………71
Figure 3.10. S-Nitrosylation-induced thermodynamic stabilization of STIM1 23-213...74
Figure 3.11. 1H-15N-HSQC spectrum of STIM1 58-201 (EF-SAM) mixed with nitroxide
spin-labelled STIM1 24-57………………………………………………………………76
Figure 3.12. Transient binding between STIM1 24-57 and STIM1 58-201 (EF-SAM)…77
Figure 3.13. Structure of the EF-SAM domain under Ca 2 + loaded condition
(2K60.pdb)……………………………………………………………………………….78
Figure 3.14. Dynamic light scattering (DLS) of STIM1 23-213 Trp121Glu/Lys122Glu
double mutant protein……………………………………………………………………80
Figure 3.15. Effect of STIM1 siRNA and BTP2 on cardiomyocyte size………………..83
Figure 3.16. Effect of GSNO treatment on cardiomyocyte size………………………....84
Figure 3.17. Effect of ectopic Adenoviral nNOS expression on cardiomyocyte size…...85
Figure 4.1. Proposed model of S-nitrosylation mediated suppression of STIM1 activity
and cardiomyocyte hypertrophy…………………………………………………………99

xi

List of Abbreviations
AEC

anion exchange chromatography

ANS

8-anilinonaphthalene-1-sulfonic acid

APC

antigen-presenting cell

AV

atrioventricular

BTP2

3,5-bistrifluoromethyl pyrazole derivative

Ca2+

calcium

CaM

calmodulin

CaN

calcineurin

CC

coiled-coil

CD

circular dichroism

cEF

canonical EF-hand

CRAC

Ca2+ release activated Ca2+

CSP

chemical shift perturbation

Cys

cysteine

DLS

dynamic light scattering

DTT

dithiothreitol

EDTA

ethylenediaminetetraacetic acid

eNOS

endothelial nitric oxide synthase

ER

endoplasmic reticulum

GFP

green fluorescent protein

GPCR

G-protein-coupled receptor

Gs

G-stimulatory alpha subunit

GSNO

S-nitrosoglutathione

HCM

hypertrophic cardiomyopathy

HSQC

heteronuclear single quantum coherence

iNOS

inducible nitric oxide synthase

IP3

inositol 1,4,5-trisphosphate

IP3R

inositol 1,4,5-trisphosphate receptor

IPTG

isopropyl β-D-1-thiogalactopyranoside

K+

potassium

xii

Kd

equilibrium dissociation constant

LB

Luria-Bertani broth

LV

left ventricular

MI

myocardial infarction

nEF

non-canonical EF-hand

NFAT

nuclear factor of activated T-cells

Ni-NTA

nickel-nitrilotriacetic acid

NMR

nuclear magnetic resonance

nNOS

neuronal nitric oxide synthase

NO

nitric oxide

NOS

nitric oxide synthase

PE

phenylephrine

PLC

phospholipase C

PM

plasma membrane

RCI

random coil index

SAM

sterile alpha motif

SEC

size-exclusion chromatography

SERCA

sarco/endoplasmic reticulum Ca2+-ATPase

siRNA

small inhibitory RNA

SNP

sodium nitroprusside

SOCE

store-operated Ca2+ entry

SR

sarcoplasmic reticulum

STIM

stromal interaction molecule

Tm

apparent midpoint of temperature denaturation

WT

wild type

1

Chapter 1

Introduction

1.1 Overall goals
Calcium (Ca2+) ions are universal signaling entities regulating numerous processes
including programmed cell death, homeostasis, gene transcription as well as muscle
contraction (Berridge et al., 2003; Mukherjee and Brooks, 2014; Orrenius et al., 2015).
Store-operated Ca2+ entry (SOCE) is a Ca2+ signaling mechanism where extracellular
Ca2+ entry is mobilized by the initial release of intracellular Ca2+ store (Putney, 1986).
Specifically, upon sarcoplasmic reticulum (SR) Ca2+ depletion, the luminal Ca2+ sensor
stromal interaction molecule-1 (STIM1) becomes activated, oligomerizes, translocates to
SR-plasma membrane (PM) junctions and interacts with Orai1 on the sarcolemma (Liou
et al., 2005; Roos et al., 2005; Stathopulos et al., 2006; Zhang et al., 2005; Zhou et al.,
2010a); thus, facilitating the formation of Ca2+ release-activated Ca2+ (CRAC) channels
by the recruited Orai1 (Feske et al., 2006; Prakriya et al., 2006; Vig et al., 2006a; Vig et
al., 2006b; Zhou et al., 2010b) and enabling Ca2+ to move down its concentration gradient
into the cardiomyocyte (Voelkers et al., 2010). The sustained elevation in cytosolic Ca2+
concentration activates the calcineurin-NFAT pathway which upregulates the expression
of pro-hypertrophic genes causing cardiomyocyte hypertrophy (Hogan et al., 2003;
Musaro et al., 1999).
Nitric oxide (NO) is a chemical compound produced in the body by a group of proteins
called nitric oxide synthases (NOS). In particular, neuronal NOS (nNOS) is found on the
SR membrane in cardiomyocytes and has been shown to regulate Ca2+ handling proteins
through the addition of NO groups onto reduced Cys residues to form S-nitrosocysteines
in a process known as S-nitrosylation (Burger et al., 2009; Gonzalez et al., 2007). A host
of over 1,000 proteins are found to be targets for S-nitrosylation in the heart alone
(Haldar and Stamler, 2013). However, the effects of S-nitrosylation on STIM1 which is
also anchored on the SR membrane and the downstream consequences of nNOS mediated
STIM1 S-nitrosylation on cardiomyocyte hypertrophy are unknown. Therefore, the goals
of this study are to examine the effects of S-nitrosylation on structure and Ca2+ sensing
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function of STIM1 and to determine how nNOS-mediated STIM1 S-nitrosylation is
involved in regulating phenylephrine (PE)-induced cardiomyocyte hypertrophy.

1.2 Calcium
1.2.1 General functions of Ca2+
Ca2+ ions are essential in mediating the proper functioning of countless processes.
Interestingly, Ca2+ promotes the formation of a new life where cytosolic Ca2+ elevation
facilitates metabolic activity of the fertilized egg and initiates embryonic development
(Santella et al., 2004). Alternations to Ca2+ signaling can also lead to apoptosis by
working in concert with various cell death inducers like members of the Bcl-2 protein
family (Pinton et al., 2008). Many vital functions of Ca2+ ions are mediated through the
action of Ca2+ binding proteins. One of the well-known proteins that rely on its
interaction with Ca2+ is calmodulin (CaM), which is ubiquitously expressed in eukaryotes
and regulates downstream proteins based on its Ca2+ binding status (Kaleka et al., 2012).
It has also been shown that Ca2+ acts as a main signaling molecule that regulates the force
of muscle contraction, rate of muscle relaxation as well as muscle plasticity, and
mutations to Ca2+ handling proteins can lead to detrimental pathological conditions like
malignant hyperthermia (due to severe muscle contractions) and muscular dystrophies
(Berchtold et al., 2000; Mickelson and Louis, 1996; Straub and Campbell, 1997). The
positively charged Ca2+ can mask negative charges of carboxyl groups in proteins like
15-lipoxygenase, an essential cytosolic enzyme involved in hematopoietic cell
differentiation, which allows these proteins to undergo membrane translocation while
avoiding disruption of the lipid bilayer (Brinckmann et al., 1998). Another function of
Ca2+ involves the regulation of neurotransmitter release, where voltage-gated Ca2+
channels mediate the transient local increase in cytosolic Ca2+ levels, synaptotagmin
activation and ultimately the exocytosis of neurotransmitter vesicles from the presynaptic
terminal (Südhof, 2012). Moreover, modulation of Ca2+ levels is a current approach for
cancer treatment since it is involved throughout the course of cancer development from
proliferation to invasion and metastasis (Stewart et al., 2015).
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1.2.2 Ca2+ function in the immune system
Ca2+ ions play a crucial role as a second messenger in the immune system. For instance,
rapid increase in cytosolic Ca2+ traveling through gap junctions to the wounded epidermis
is necessary for attracting immune cells to the site of injury and triggering the
inflammatory response (Razzell et al., 2013). In the long term, sustained Ca2+ elevation in
the T cell can occur as a result of an immunological synapse (IS) following the
association between a T lymphocyte and an antigen-presenting cell (APC). T cells have a
lower level of Ca2+ stores compared to other non-excitable cells due to the smaller
intracellular space available while accommodating the central nucleus (van der Loo et al.,
1981) and the leaky ER membrane (Le Gall et al., 2004). The rise in cytosolic Ca2+
concentration is mediated by the phospholipase C (PLC) and inositol 1,4,5-trisphosphate
(IP3) signaling pathway, which triggers the release of the small Ca2+ stores. These
cytosolic Ca2+ ions can initiate the opening of PM Ca2+ channels that allows more Ca2+
ions to enter and play important roles in T-cell regulation. The activation of a Ca2+
dependent protease, calpain, has been found to mediate T-cell immobilization; thus,
allowing T cells to change its membrane shape to better associate with APCs. Ultimately,
Ca2+-dependent upregulation of specific genes is necessary, following antigen detection
by surface receptors, for initiating T-lymphocyte and B-lymphocyte activation as a part
of the secondary immune response (Randriamampita and Trautmann, 2004). It is
important to note that these aforementioned examples are just a few of the essential
pathways and processes regulated by Ca2+ and by no means constitute an exhaustive list.

1.2.3 Intracellular Ca2+ compartmentalization
In order to closely regulate these processes mentioned above, Ca2+ is compartmentalized
with a high extracellular concentration (~1 mM) and a low cytosolic concentration
(~ 0.0001 mM) under basal conditions (Hunton et al., 2002). Moreover, Ca2+ is stored in
many intracellular organelles such as the endo/sarcoplasmic reticulum (ER/SR),
mitochondria and Golgi apparatus (Alonso et al., 2006; Ashby and Tepikin, 2001; Collins
et al., 2013). Under resting conditions, Ca2+ concentrations in the cytosol and
mitochondria are similarly low (~ 0.0001 mM). However, the mitochondria can act as a
temporary storage for Ca2+ in the form of the Ca2+ phosphate complex in order to prevent
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cellular Ca2+ overload and apoptosis mediated by protease and PLC activation (Nicholls,
2005; Pinton et al., 2008). Therefore, a much higher mitochondrial Ca2+ concentration
(~0.05 mM) is found following cell activation and elevation of local cytosolic Ca2+ levels
(Alonso et al., 2006). After mitochondrial Ca2+ uptake, the Ca2+ is quickly dissipated by
Na+/Ca2+ exchangers (Boyman et al., 2013). The Golgi apparatus has been shown to
accumulate Ca2+ (~0.3 mM) in resting HeLa cells which can be rapidly released upon
histamine-induced IP3 production (Pinton et al., 1998). On the other hand, the largest
intracellular organellar Ca2+ store is the ER/SR, containing a high Ca2+ concentration
(~0.4-0.7 mM) that can be released into the cytosol when needed in response to certain
electrical or chemical signals (Collins et al., 2013).
The virtually inexhaustible extracellular source of Ca2+ is essential for both excitationmediated cytosolic Ca2+ elevation as well as ER/SR Ca2+ store repletion (Hofer and
Brown, 2003). Typically, the release of intracellular Ca2+ from stores also causes
extracellular Ca2+ entry that together augment the cytosolic Ca2+ levels, after receiving
specific voltage dependent and independent signals, in order to quickly initiate the
activation of Ca2+ dependent pathways (Putney, 1986). The movement of extracellular
Ca2+ into the cell replenishes the depleted stores, as important Ca2+-dependent processes
take place in the ER including protein folding and chaperone function (Araki and Nagata,
2011; Braakman and Hebert, 2013).

1.2.4 Ca2+ signalling impairments in the heart
Studies have indicated that impairments to normal Ca2+ signalling can lead to serious
pathological conditions. For instance, it was found that abnormal Ca2+ handling and
reduced ryanodine receptor (RyR) inactivation leads to cardiac arrhythmia (Chang et al.,
2014). RyR2 mutations (Trp3587Ala/Leu3591Asp/Phe3603Ala) in the CaM binding
domain in mice lead to pathological cardiac hypertrophy, reduced left ventricular
contractility and fatality shortly after birth (Arnaiz-Cot et al., 2013). On the other hand,
CaM mutations (Asn54Ile and Asn98Ser) are associated to patients with ventricular
tachycardia and sudden cardiac arrest (Nyegaard et al., 2012). Moreover, heart failure is
associated with increased SR Ca2+ store depletion through the leaky RyR2 as well as
decreased SERCA2a expression and activity (Lipskaia et al., 2010). The reduction in SR
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Ca2+ concentration is responsible for the decreased contractility characteristic of heart
failure (Park and Oh, 2013). Additionally, Ca2+ leaked from the SR can trigger fatal
cardiac arrhythmias (Yano et al., 2005). Higher resting intracellular Ca2+ may be
responsible for contracture or impairment of relaxation function of the heart, ultimately
leading to diastolic heart failure (Periasamy and Janssen, 2008). The ability for Ca2+ to
control so many physiological processes demonstrates how essential it is to understand
the functional mechanisms of proteins involved in Ca2+ regulation and the pathways that
control Ca2+ signalling. A critical pathway that links both extracellular Ca2+ entry and
stored Ca2+ release from the ER/SR is SOCE (Roberts-Thomson et al., 2010).

1.3 SOCE and CRAC channels
SOCE is a conserved Ca2+ signaling mechanism from lower eukaryotes like the fruit fly
to higher vertebrates including mouse and human (Cai, 2007; Molnar et al., 2012;
Redondo et al., 2006; Yeromin et al., 2004). The SOCE model was first proposed as a
mechanism where extracellular Ca2+ entry is mobilized by the initial release of
intracellular Ca2+ store and triggered by agonist binding to surface membrane receptors
(Putney, 1986). The essential components involved in SOCE including the ER/SR Ca2+
sensor and PM Ca2+ channel subunits were identified later to be STIM (Liou et al., 2005;
Roos et al., 2005; Zhang et al., 2005) and Orai (Feske et al., 2006; Prakriya et al., 2006;
Vig et al., 2006a; Vig et al., 2006b) proteins, respectively. Transient receptor potential
(TRP) channels were considered as the main mediators of SOCE (Mignen et al., 2008)
and CRAC signalling before STIM and Orai proteins were recognized (Dráber and
Dráberová, 2005; Parekh and Penner, 1997; Parekh and Putney, 2005; Varga-Szabo et al.,
2009). TRP channels were found to form cation channels and mediate Ca2+ influx
(Freichel et al., 2012), but these Ca2+ entry pathways are not CRAC channels which are
exclusively constituted by Orai proteins (Feske et al., 2006; Prakriya et al., 2006). SOCE
is a Ca2+ mobilization event that can be initiated following the activation of many
different PM receptors, including receptor tyrosine kinases (RTK), T-cell receptors
(TCR) and G-protein-coupled receptors (GPCR), which all cause IP3 production and Ca2+
store depletion (Cantrell, 2002; Salazar et al., 2007; Schlessinger, 2000; Werry et al.,
2003).
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The importance of Ca2+ signalling in the heart was first recognized over 130 years ago
where it was shown that the heart could not beat without the presence of Ca2+ ions in the
circulating fluid (Ringer, 1883). In cardiomyocytes, SOCE coexists with voltage-gated
Ca2+ entry that is mediated by L-type Ca2+ channels (LTCC) on the sarcolemma and
RyRs on the SR following membrane depolarization (Collins et al., 2013; Tojyo et al.,
2014). Although there are three isoforms of RyR, RyR1 is highly expressed in the
skeletal muscle (Zorzato et al., 1990), RyR3 is found in the brain (Hakamata et al., 1992),
whereas RyR2 is in cardiac muscles and regulates excitation-contraction coupling by
controlling SR Ca2+ store release (Taur and Frishman, 2005). Interestingly, cardiac RyR2
was found to be susceptible to phosphorylation on serine residues and this posttranslational modification seems to effect the progression of various cardiovascular
diseases (Dobrev and Wehrens, 2014). RyR2 mutations are linked to various heart
conditions where Arg4496Cys is associated with impaired contractile function of atrial
and ventricular myocardium (Ferrantini et al., 2016), whereas Asn4104Lys, Arg4496Cys
and Asn4895Asp are linked to ventricular tachycardia and sudden death (Jiang et al.,
2004). The initiation of the excitation-contraction coupling process begins with
membrane depolarization-mediated activation of LTCCs, followed by the local
intracellular Ca2+ elevation mediated activation of junctional SR RyR2s, which ultimately
enables the accumulation of a high intracellular Ca2+ concentration globally which
induces heart muscle contractions (Hund et al., 2008). This process is termed Ca2+
induced Ca2+ release since the local Ca2+ elevation stimulates further SR Ca2+ release
from RyR2 channels.
SOCE is facilitated by the activation of CRAC channels, which is crucial for Ca2+
signalling in response to oxidative stress (Mungai et al., 2011) (Figure 1.1). An initial
stimulation, such as the binding of a ligand to its receptor, may lead to the production of
secondary messengers and downstream events that cause the release of Ca2+ from
intracellular stores like the ER/SR. For example, upon activation of specific GPCRs by
agonists such as phenylephrine (PE), endothelin 1 (ET-1) and angiotensin II (ANG II),
phosphatidyl inositol 4,5-bisphosphate (PIP2) is converted into IP3 via the action of PLC.
The specific mechanisms of GPCR activation are discussed in more detail below. IP3 can
act as a second messenger that diffuses from the sarcolemma to the ER/SR, where it
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binds to IP3 receptors (IP3R) anchored on the ER/SR membrane (Wang et al., 2005).
IP3Rs form transmembrane (TM) channels that can adopt an open conformation
following the binding of IP3 and allow the release of Ca2+ from the ER/SR into the
cytoplasm (Yoshida and Imai, 1997). However, the ER/SR Ca2+ store is limited.
Therefore, to maintain sustained Ca2+ elevation in the cytosol, extracellular Ca2+ entry
through the sarcolemma is required. The SR Ca2+ depletion triggers the assembly and
activation of Orai1 CRAC channels in the SOCE pathway, allowing Ca2+ influx from the
extracellular space and replenishing the ER/SR through the action of SR/ER Ca2+ATPase (SERCA) (Parekh and Putney, 2005). The sustained elevation of cytosolic Ca2+
causes the activation of the calcineurin-nuclear factor of activated T cells (NFAT)
pathway. The details of this cardiomyocyte hypertrophy-inducing pathway are described
in section 1.4.
Overall, the LTCC and RyR2 mediated Ca2+ induced Ca2+ release is responsible for the
fast and high amplitude Ca2+ oscillation during heart contractions (Taur and Frishman,
2005), whereas STIM1 and Orai1 mediated SOCE signalling enables longer and lower
level Ca2+ increases for transcriptional regulation via the calcineurin-NFAT pathway
(Hogan et al., 2003).
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1.4 Stromal interaction molecule (STIM) and Orai
As previously described, the process of SOCE via CRAC channels is vital for Ca2+
signalling in both excitable and non-excitable cells. Two proteins that are essential for the
activation, formation and regulation of CRAC channels are STIM and Orai, both of
which are found in cardiomyocytes (Voelkers et al., 2010). STIM proteins function as
ER/SR Ca2+ sensors and CRAC channel activators (Liou et al., 2005; Zhang et al., 2005),
whereas Orai proteins are the structural components that form the CRAC channels and
mediate Ca2+ entry into the cytosol (Feske et al., 2006; Voelkers et al., 2010; Zhang et al.,
2011). Interestingly, coexpression of STIM1 and Orai1 in human embryonic kidney
(HEK)-293 and rat basophilic leukemia cells has been found to induce enormous Ca2+
entry rates which are 103-fold higher compared to vector control cells, whereas
expression of Orai1 alone has been shown to attenuate SOCE in the same cell types
(Soboloff et al., 2006). In addition, STIM1 or Orai1 knockout mice generally die in utero
or shortly after birth from respiratory and immunological complications (Cahalan, 2009;
Vig et al., 2008). Several heritable STIM1 and Orai1 mutations have been identified in
patients suffering from debilitating immunodeficiency diseases (Feske, 2009). These
findings emphasize the importance of STIM and Orai proteins in mediating physiological
SOCE functioning and CRAC currents in health and disease.

1.4.1 STIM domain organization
STIM proteins are essential Ca2+ sensors and SOCE activators that can be found in most
eukaryotic tissues critical for maintaining normal human physiology as well as mediating
pathophysiological changes (Ambily et al., 2014; Cui et al., 2017; Darbellay et al., 2010;
Wang et al., 2016; Zhou et al., 2014). There are two main human homologues that are
highly similar in both protein sequence and domain architecture, STIM1 (685 residues)
and STIM2 (746 residues for isoform 2) (Hooper et al., 2013). Human STIM1 is a type I
TM protein consisting of several luminal and cytosolic domains working in concert to
regulate the activation of CRAC channels in the SOCE pathway (Figure 1.2A). On the
other hand, the homologous STIM2 functions as the main regulator of basal Ca2+
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homeostasis (Brandman et al., 2007). Although the activity of STIM2 also depends on
stored Ca2+ levels, it becomes activated even when the stores are near full, likely due to
the weaker Ca2+ binding affinity of STIM2 (Gruszczynska-Biegala et al., 2011;
Stathopulos et al., 2013; Zheng et al., 2008; Zheng et al., 2011).
In the luminal region of STIM1 downstream of its signal peptide, there are two conserved
cysteine residues (Cys49 and Cys56), the canonical EF-hand (residues 63-96) and noncanonical EF-hand (residues 97-128) domains, as well as a sterile α motif (SAM)
(residues 132-200) which are essential for mediating the Ca2+ sensing function of STIMs,
enabling its downstream activation under Ca2+ depletion (Figure 1.2B). Initially, results
from sequence analysis were only able to reveal a single canonical EF-hand; however, the
three dimensional (3D) structure of STIM1 exposed the presence of a non-canonical EFhand followed by a SAM domain that is connected via a linker region. The non-canonical
EF-hand forms hydrogen (H)-bonds with the canonical EF-hand and forms a pocket for
interactions with the SAM domain in the presence of Ca2+. When the canonical EF-hand
loses Ca2+, the protein undergoes a partial unfolding destabilization, coupled with
oligomerization which is the initiation event for SOCE activation (Stathopulos et al.,
2006; Stathopulos et al., 2009; Stathopulos et al., 2008).
Live cell fluorescence resonance energy transfer (FRET) and total internal reflective
fluorescence (TIRF) experiments showed that ER luminal Ca2+ depletion leads to the
oligomerization and translocation of STIM1 as illustrated by the formation of distinct
STIM1 punctate aggregates at ER-PM junctions (Liou et al., 2007; Mercer et al., 2006;
Spassova et al., 2006; Stathopulos et al., 2013). Moreover, when the luminal EF-SAM
region of STIM1 was replaced by the rapamycin-binding protein, FK506-binding protein
(FKBP12), the addition of rapamycin itself was sufficient to induce oligomerization of
this resultant chimeric protein and initiate its translocation to the ER-PM junctions,
leading to activation of CRAC channels even with replete ER Ca2+ stores (Luik et al.,
2008). However, when the SAM domain was deleted, agonist stimulation was unable to
induce STIM1 puncta accumulation near the junction (Baba et al., 2006). Collectively,
these data show that oligomerization is required for translocation of STIM1 to ER-PM
junctions and activation of Orai1 channels.
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After the single-pass TM domain, the three coiled-coil (CC) regions, CC1 (residues 238343), CC2 (residues 363-389) and CC3 (residues 399-423) are critical for facilitating the
interaction between STIM and Orai proteins. The CC regions also contribute to stable
STIM1 oligomerization upon ER Ca2+ depletion which was illustrated through the
inability of STIM1 mutants lacking cytosolic region to relocalize and form puncta
(Covington et al., 2010). The CC regions can also be grouped into three overlapping
functional fragments including the Orai1 activating small fragment, OASF (residues 233450), CRAC activating domain, CAD (residues 342-448) as well as STIM1-Orai1
activating region, SOAR (residues 344-443), all of which are able to induce Orai1
activation and CRAC channel formation (Muik et al., 2009; Park et al., 2009; Yuan et al.,
2009). Importantly, CAD (i.e. CC2-CC3) is the minimal coupling and activating Orai1
region.
There are also several distinct regions downstream of the three CC domains near the Cterminus, an acidic inhibitory domain (ID) (residues 470-491) that is necessary for rapid
Orai1 inactivation in the presence of ER luminal Ca2+ (Derler et al., 2009; Lee et al.,
2009; Mullins et al., 2009), a proline-serine (PS) rich region (residues 600-629) where
several Ser residues undergo phosphorylation, as well as a polybasic lysine (Lys) rich
region (residues 671-685) which associates with PM phospholipids; deletion of the
polybasic C-terminus disrupts puncta formation (Barr et al., 2009). Ultimately, the EFSAM, TM domain, CCs, PS and K regions of STIM are well conserved from lower to
higher order species and play vital roles in the proper functioning of the STIM protein
(Stathopulos et al., 2013) (Figure 1.2B).
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1.4.2 Orai domain organization
Orai proteins contain four TM components and predominantly localize at the PM (Cai,
2007; Feske, 2007). They were first identified as the CRAC channel pore forming
proteins in 2006 (Feske et al., 2006; Prakriya et al., 2006; Yeromin et al., 2006) and were
found to mediate SOCE across different species. A Drosophila melanogaster Orai (132341) quadruple mutant (Cys224Ser/Cys283Thr/Pro276Arg/ Pro277Arg) crystal structure
has been solved, where the TM regions are over 70 percent conserved compared to
human Orai1 (Hou et al., 2012). The D. melanogaster crystal has a six-fold symmetry
that supports the formation of a hexameric quaternary structure. Both hexameric and
tetrameric models have been proposed for assembled and activated human Orai1
(Demuro et al., 2011; Maruyama et al., 2009; Mignen et al., 2008; Penna et al., 2008;
Thompson and Shuttleworth, 2013). Within the TM1 domain in the channel pore region
near the extracellular space, residue Glu178 from D. melanogaster Orai crystal and
Glu106 from human Orai1 are necessary for the protein to specifically bind Ca2+ and
selectively allow ions to enter the cell. Moreover, the development of a form of heritable
severe combined immunodeficiency (SCID) is caused by intracellular TM1 residue
Arg91Trp mutation in H. Sapiens (Lys163Trp in D. melanogaster). The crystal structure
revealed that this disease-associated mutation introduces a bulky hydrophobic Trp residue
to the exposed TM1 pore surface of Orai1 which interferes with Orai1 CRAC channel
activity and Ca2+ entry (Hou et al., 2012).
Both the N- and C-termini of Orai are protruding in the cytosol and play important roles
in interacting with the cytosolic regions of STIM1, which are necessary for Orai
activation and CRAC channel formation (Frischauf et al., 2009; Muik et al., 2008; Muik
et al., 2012; Park et al., 2009; Stathopulos et al., 2013; Yuan et al., 2009; Zheng et al.,
2013; Zhou et al., 2010a). At resting state, Orai1 C-terminal domain extending from the
TM4 region associates in pairs to form a stable antiparallel structure which interacts with
the STIM1 CC region at ER-PM junctions (Stathopulos et al., 2013). The antiparallel
orientation of the C-terminal helices within these dimers elucidated in the D.
melanogaster Orai crystal structure shows structural compatibility with the NMR
structure of the human CC1-CC2 STIM1 region in complex with the human Orai1 C-
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terminal peptides suggesting a mechanism for coupling between STIM1 and Orai1
(Stathopulos et al., 2013).
The three human homologues, Orai1, Orai2 and Orai3, contain highly conserved TM
regions and linker regions as well as conserved acidic and basic residues necessary for
channel function including Ca2+ ion permeability and selectivity (Stathopulos et al.,
2013). All three forms of human Orai protein can be activated by STIM following
exogenous expression and can assemble into CRAC channels with different biophysical
characteristics based on the combination of STIM and Orai in specific cells (DeHaven et
al., 2007; Frischauf et al., 2009; Lis et al., 2007). However, Orai1 is the only homologue
that constitutes the endogenous homomeric CRAC channel. Structural elucidation of the
Orai1 protein via electron microscopy indicates that it has an extended teardrop-shape
and a 10 nm cytoplasmic region which mediates its association directly with STIM1
(Maruyama et al., 2009).

1.4.3 STIM1 and Orai1 function
SOCE activation via CRAC channels is a multi-step process involving many molecular
players, notably STIM1 and Orai1. As previously mentioned, STIM1 is an ER/SR Ca2+
sensor that binds to, assembles and gates CRAC channels (Zhao et al., 2015). Studies
have indicated that the EF-SAM domains of STIM1 are essential for detecting changes in
luminal Ca2+ concentrations (Stathopulos et al., 2006) while regions of the long putative
CC1 and short CC2 and CC3 domains directly interact with and activate Orai1-composed
CRAC channels (Stathopulos et al., 2013).
When Ca2+ concentration in the ER/SR lumen is high, Ca2+ binds to the EF-SAM region
of STIM1 and keeps it in an inactive state. Following Ca2+ release from the ER/SR
through particular channels like the IP3R, low luminal Ca2+ levels results in the loss of
bound Ca2+ to the EF-SAM domain and triggers the destabilization and oligomerization
of the EF-SAM domain. This process initiates structural changes on the cytosolic side of
STIM1 which leads to the conformational extension and oligomerization of the CC
region. These structural changes then result in the translocation of STIM1 to the ER/SRPM junctions and the recruitment of Orai subunits to the same sites that form the CRAC
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channel complex (Stathopulos et al., 2013). This interaction between STIM1 and Orai1
ultimately induces the opening of CRAC channels made up of Orai1 molecules selective
for Ca2+ ions and produces the inward current caused by Ca2+ entry down its
concentration gradient into the cytosol (Stathopulos et al., 2008).
Active CRAC channels constituted of Orai1 subunits can be inactivated by the CRAC
modulatory domain within STIM1 and CaM in a process termed Ca2+ dependent
inactivation (CDI) (Derler et al., 2009; Mullins et al., 2009; Roos et al., 2005). STIM1
residues 470-491 downstream of the CC3 domain containing 7 acidic residues were
found to be vital for STIM1 to rapidly exert its role in the CDI process (Mullins et al.,
2009). Interestingly, CaM has been found by various studies to interact with the
polybasic region of both STIM1 (667-685) and STIM2 (730-746) C-terminal regions
with μM affinity in a Ca2+ dependent manner (i.e. ~1 μM with Ca2+ and ~ 100 μM
without Ca2+) and prevent STIM protein from translocating to ER-PM junctions (Bauer
et al., 2008; Calloway et al., 2011; Korzeniowski et al., 2009; Walsh et al., 2009; Yuan et
al., 2009).
A key step in the initiation of SOCE is the destabilization and activation of STIM1 in
response to depleted ER/SR Ca2+ stores (Stathopulos et al., 2006). Thus, an in depth
study of modifications that influence STIM1 stability will reveal important new insights
on the regulation of SOCE. Previous studies have found that the coiled-coil (CC) regions
of STIM1 alone are capable of assembling Orai1 into CRAC channels by forming a
multimeric structure and binding to the cytoplasmic surface of Orai1 (Kawasaki et al.,
2009; Stathopulos et al., 2013). However, several aspects concerning the regulation of the
STIM1 N-terminal region and its allosteric effect on the STIM1 CC regions and on the
activation of Orai1 still need to be elucidated. The short, non-conserved N-terminal
regions of STIM1 and STIM2, containing two modifiable cysteine residues, have been
shown to modulate the stability of the Ca2+-sensing EF-SAM core and thereby the
activation of SOCE (Stathopulos et al., 2009; Zhou et al., 2009); thus, it is prudent to
study the effect of specific modifications of residues in this region on the overall function
of STIM. Moreover, since many studies have detected STIM1 in cardiomyocytes and
SOCE is known to play a central role in cardiac hypertrophy, investigations on the
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precise molecular mechanisms of SOCE regulation will reveal important insights into the
underlying pathophysiological signals contributing to heart dysfunction (Hulot et al.,
2011; Hunton et al., 2002; Luo et al., 2012; Zhu-Mauldin et al., 2012).

1.5 Cardiac hypertrophy
The human heart is a vital organ in the circulatory system that works continuously
through one’s lifespan of likely over 80 years. While pumping blood throughout the
circulatory system, the heart is often exposed to a myriad of electrical and chemical
stimuli that could be physiological or pathophysiological and needs to react promptly to
meet these demands in an appropriate manner. Transient stress can cause the heart to
respond with reversible hyperfunction and return back to basal conditions once the
stressor is no longer present. However, when stress on the heart becomes persistently
high, often due to high blood pressure, valve dysfunction or myocardial infarction (MI),
the heart increases its ventricular wall thickness in order to maintain the necessary level
of cardiac output. This chronic compensatory hyperfunction of the heart can cause
progressive cardiac dilation and dysfunction that ultimately lead to the development of
severe disease conditions including pathological cardiac hypertrophy and heart failure
(Tardiff, 2006).

1.5.1 Physiological and pathological hypertrophy
Cardiac hypertrophy is characterized by an enlargement of the heart muscle due to an
increase in cardiomyocyte size. This resultant phenotype is developed because adult
cardiomyocytes have lost the ability to replicate themselves and can only grow by
increasing their cell size (Soonpaa et al., 1996). Not all forms of cardiac hypertrophy are
disease related. For instance, physiological hypertrophy can develop in athletes, which
results in normal if not enhanced cardiac function (Pluim et al., 2000). A trained athlete’s
heart has distinct morphological differences, including a higher ventricular wall
thickness, elevated left ventricular volume and heart weight, due to the increased cardiac
output, pressure and volume overload experienced during intense exercise regimens
(Fagard, 1997; Pluim et al., 2000; Spirito et al., 1994). On the other hand, pathological
cardiac hypertrophy can stem from conditions such as MI, high blood pressure and
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particular genetic mutations of sarcomere proteins (Levy et al., 1988; Seidman and
Seidman, 2001). For patients with pathological cardiac hypertrophy, otherwise known as
hypertrophic cardiomyopathy, monitoring left ventricular wall thickness using
echocardiography can indicate the extent of disease progression. The increased maximal
ventricular wall thickness directly correlates with poorer treatment prognosis and an
elevated risk for sudden death even in the absence of symptoms (Spirito et al., 2000).
Moreover, pathological cardiac hypertrophy is accompanied by an increase in proinflammatory cytokines, impaired cell signaling as well as the development of cardiac
fibrosis (Shimizu and Minamino, 2016). There are many intracellular mechanisms that
contribute to the development of physiological and pathological cardiac hypertrophy.
Studies have found an increase in fatty acid and glucose oxidation during exercise in
humans (Gertz et al., 1988), whereas cells from pathologically hypertrophied hearts have
lower fatty acid oxidation and elevated glucose metabolism (Allard et al., 1994; Christe
and Rodgers, 1994; Davila-Roman et al., 2002). The initial onset of increased glucose
metabolism is likely a compensatory mechanism aimed at protecting the heart by
producing more ATP (van Bilsen et al., 2009). However, as the disease progresses, the
development of insulin resistance effectively cripples the ability of the hypertrophied
heart to produce the necessary ATP and contributes to the development of other
comorbidities (Kolwicz and Tian, 2011; Neubauer, 2007; Paternostro et al., 1999).

1.5.2 Intracellular signalling pathway
Many receptors and pathways under investigation are associated with the development of
pathological cardiac hypertrophy. For instance, it has long been revealed that GPCRs are
vital in mediating cell signaling, regulating protein expression and interacting with other
receptors in cells from the cardiovascular system (Salazar et al., 2007; Tang and Insel,
2004). Typically, this pathway is initiated when a ligand binds to the GPCR (see below),
causing this PM protein to change in conformation and couple with heterotrimeric
guanine-nucleotide regulatory proteins (G proteins) containing α, β and  subunits, which
then dissociate and activate downstream effectors. The Gα subunit includes Gαs which is
stimulatory and becomes activated upon β-adrenergic receptor (AR) stimulation, Gαi that
is inhibitory following ligand binding to a muscarinic receptor, and Gαq which is
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stimulated as a result of α1-AR activation. The downstream effector for Gαs and Gαi is
adenylyl cyclase, whereas PLC acts as the effector for Gαq and produces secondary
messengers IP3 and diacylglycerol (DAG) following activation (Luttrell, 2006).
Studies have shown that in cardiomyocytes, the GPCRs associated with Gαq activation,
including the previously mentioned α1-AR, ANG II and ET-1 receptors, can all mediate
the development of cardiac hypertrophy via the calcineurin-NFAT pathway and often
work in concert with the mitogen-activated protein kinase (MAPK) pathway (Knowlton
et al., 1993; Sugden, 1999). Interestingly, transgenic mice overexpressing Gαq exhibit
cardiomyocyte hypertrophy, heart weight elevation, myocardial contractility impairment,
fractional shortening attenuation, biventricular failure and higher mortality (D'Angelo et
al., 1997), while cardiac specific overexpression of ANG II receptor leads to the
development of an abnormally slow heart rate and death a few weeks after birth (Hein et
al., 1997). On the other hand, inhibition of Gαq signaling by overexpression of a Gαq
inhibitory peptide results in substantial attenuation of cardiac hypertrophy and MAPK
activation following transverse aortic constriction-induced pressure overload (Akhter et
al., 1998; Esposito et al., 2001).
Transgenic overexpression of Gαs protein in the heart has also been found to mediate the
development of cardiomyocyte hypertrophy, myocardial fibrosis and apoptotic cell death
leading to heart failure in mice (Gaudin et al., 1995; Iwase et al., 1996). The protein
kinase B (Akt) and mammalian target of rapamycin (mTOR) signaling pathway is also
shown to be involved in pathological hypertrophy, in which mTOR overexpression
mitigates the inflammatory reaction in cardiomyocytes and prevents the cardiac
dysfunction that typically occurs after pressure overload (Song et al., 2010).

1.5.3 Role of Ca2+ and SOCE
Following PE-mediated activation of its corresponding GPCR [alpha-1 (α1)-AR] which is
associated with the heterotrimeric protein Gαq, the production of IP3 by PLC triggers the
activation of IP3R on the ER/SR membrane and the Ca2+-depletion mediated activation of
the SOCE pathway. Sustained increases in intracellular Ca2+ levels mediated by SOCE
results in the activation of calcineurin, a Ca2+ and CaM-dependent protein phosphatase,
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which cleaves a phosphate group off NFAT. The dephosphorylated transcription factor
NFAT then translocates into the nucleus to upregulate the transcription of prohypertrophic genes (Hogan et al., 2003; Musaro et al., 1999).

1.6 Nitric oxide synthase
NO is a chemical compound ubiquitously produced in the body by a group of proteins
called NOS and has been shown to play an important role in regulating contractility,
excitation-contraction coupling as well as hypertrophic signalling in cardiomyocytes
(Kelly et al., 1996). There are three isoforms of NOS, namely, nNOS, inducible NOS
(iNOS) and endothelial NOS (eNOS) that differ in both structure and function. nNOS and
eNOS are typically expressed constitutively and are Ca2+ dependent, whereas iNOS is
only highly expressed after inflammatory cytokine induction and is not sensitive to Ca2+
level changes (Stuehr, 1997). The three NOS homologues play vital roles in various
eukaryotic tissues.

1.6.1 iNOS
The expression of iNOS can be induced by particular cytokines, bacterial
lipopolysaccharides and other agonists in almost any cell type (Forstermann et al., 1994).
The synthesis of NO by iNOS in macrophages is the major contributor mediating its
cytotoxic effect on downstream pathogens (Nathan and Hibbs, 1991). The large amount
of NO produced by macrophages can exert its effect by directly causing DNA
fragmentation in the target bacterial or fungal cells (Wink et al., 1991). Moreover, iNOS
expression contributes to the development of heart failure post-MI in mice (Feng et al.,
2001), which is supported by studies that show improved cardiac function post-MI
following inhibition of iNOS activity (Liu et al., 2005; Sun et al., 2009).

1.6.2 eNOS
eNOS is the predominant NOS isoform found in endothelial cells and the pulsatile
production of NO by eNOS in response to particular stimuli, such as the Ca2+-dependent
binding of calmodulin, leads to vascular smooth muscle dilation and enhanced
microcirculation (Sandoo et al., 2010). eNOS is an important regulator of blood pressure
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and its deficiency results in elevations of blood pressure (Barouch et al., 2003). In
cardiomyocytes, eNOS is found in the sarcolemma and facilitates β2-AR signalling by Snitrosylating G protein receptor kinase 2, β-arrestin2 and dynamin; thus enabling an
increase in contractility and cardiac output (Haldar and Stamler, 2013). eNOS was
identified as a necessary mediator of ginseng-induced cardioprotection during ischemia
and reperfusion (I/R). It was revealed that eNOS knockout (eNOS-/-) mice did not
experience reduced myocardial infarction even with the ginseng treatment (Wu et al.,
2011). eNOS also plays a role in atrioventricular (AV) valve development via the process
of endothelial to mesenchymal transition (EMT). eNOS-/- results in incomplete formation
of the cardiac AV valve (Liu et al., 2013) as well as the development of atrial septal
defects (ASD) and ventricular septal defects (VSD) (Feng et al., 2002). eNOS deficiency
can also result in a congenital heart defect called hypoplastic coronary artery disease that
is caused by the incomplete development of coronary arteries and linked with poor
treatment outcomes as well as high mortality rates (Liu et al., 2014).

1.6.3 nNOS
nNOS is predominantly found in the central and peripheral neurons and has been
demonstrated to play an important role in long term potentiation, learning and memory
formation (Zhou and Zhu, 2009). In cardiomyocytes, nNOS is found in the SR membrane
(Xu et al., 1999). nNOS regulates Ca2+ handling proteins such as cardiac RyRs and Ltype Ca2+ channels through S-nitrosylation, to name a few (Burger et al., 2009; Gonzalez
et al., 2007). Stimulation of integrin from neonatal rat cardiomyocytes was found to
induce the development of a hypertrophic phenotype in a NO-dependent manner (Umar
et al., 2009). Studies have indicated that nNOS is present in the SR and mitochondria of
cardiomyocytes and can modulate cellular Ca2+ concentration and transport by inhibition
of cardiac SR Ca2+-ATPase activity (Kanai et al., 2001; Xu et al., 1999). Additionally,
nNOS has been found to function as an essential regulator of basal myocardial
contractility and Ca2+ handling in left ventricular (LV) cardiomyocytes (Sears et al.,
2003). Mice with nNOS-/- have higher cardiac oxidative stress (Kar et al., 2014) as well
as increased ventricular arrhythmia and mortality after MI by left coronary artery ligation
(Burger et al., 2009). Moreover, nNOS-/- and eNOS-/- mice have elevated mortality rates,
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cardiac hypertrophy, progressive interstitial fibrosis and hypertension (Barouch et al.,
2003). nNOS overexpression in transgenic mice attenuates cardiac deterioration
following chronic pressure-overload induced heart failure by modulating Ca2+ cycling
(Loyer et al., 2008). On the other hand, the effect of nNOS overexpression in PE-induced
cardiomyocyte hypertrophy has not been well characterized.

1.7 S-Nitrosylation
Protein post-translational modifications such as phosphorylation and ubiquitination have
long been recognized as critical processes for ensuring proper signal transduction and cell
functions. It was only in the past 20 years that accumulating evidence has been
discovered emphasizing the vital regulatory role of S-nitrosylation working in concert
with many other post-translational mechanisms which includes the aforementioned
phosphorylation and ubiquitination, as well as acetylation, palmitoylation, sumoylation
and redox modifications, to name a few (Hess and Stamler, 2012).

1.7.1 Mechanism of S-nitrosylation
S-Nitrosylation is a readily reversible cysteine (Cys) modification that can occur under
the presence of an NO donor and an electron acceptor. Specifically, S-nitrosylation
involves the addition of NO groups onto reduced Cys residues to form S-nitrosocysteines
(Figure 1.3) which affects the structure and function of the S-nitrosoproteins (Gould et
al., 2013). More than 1,000 proteins are found to be S-nitrosylated in the heart alone; a
list which will likely expand with the emergence of better detection methods (Haldar and
Stamler, 2013; Hess and Stamler, 2012).

1.7.2 Effect of S-nitrosylation on different proteins
Selective S-nitrosylation of specific Cys residues was found to effect protein stability,
activation, structure, localization and function (Gould et al., 2013). S-nitrosylation of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) at Cys247 has been shown to
inhibit its ability to appropriately function as a chaperone protein, thus leading to the
ubiquitination and degradation of ribosomal protein L13a (Jia et al., 2012). Dysregulation
of particular enzymes involved with S-nitrosylation or denitrosylation often results in
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serious pathological conditions. For instance, GSNO reductase (GSNOR) is a metabolic
enzyme that selectively reduces the S-nitrosothiol group from GSNO and cellular
proteins using NADH as an electron donor. The activity of GSNOR is tightly regulated in
order to maintain physiological homeostasis and resist damage from nitrosative stress.
Since NO is physiologically produced from L-arginine via the action of NOS enzymes,
many pathological conditions stem from the dysregulation of arginine metabolic
pathways and lack of NO production, including allergic asthmas and pulmonary
hypertension (Maarsingh et al., 2006; Morris et al., 2008).

1.7.3 S-nitrosylation and cardiac function
S-nitrosylation may elevate or inhibit protein functions depending on the specific protein
it targets. For example, a recent study has shown that GSNOR overexpression in mice
inhibits isoproterenol-induced left ventricular hypertrophy, reduces interstitial fibrosis
and increases myocardial Ca2+ sensitivity by preventing S-nitrosylation of several Ca2+
handling proteins, such as cardiac troponin C, phospholamban and RyR (Irie et al., 2015).
On the other hand, GSNOR knockout (GSNOR-/-) mice have excess SNO formation
which results in blood pressure dysregulation, elevated tissue injury and increased
mortality rate following endotoxic shock (Liu et al., 2004). Interestingly, S-nitrosylation
has also been found to activate or suppress protein function depending on the specific
Cys residue being modified. S-nitrosylation of Ca2+/CaM-dependent protein kinase II at
Cys290 after Ca2+/CaM treatment leads to autonomous activation, whereas Snitrosylation of Cys273 prior to Ca2+/CaM treatment inhibits kinase activation and
reduces the effect exerted by Ca2+/CaM afterwards (Erickson et al., 2015). S-nitrosylation
also regulates the function of many ion channels that are involved in excitationcontraction coupling in cardiomyocytes (Bers, 2002). For example, S-nitrosylation by
exogenous SNP treatment or ionomycin-induced endogenous NOS activation leads to the
persistent activation of voltage-gated Na+ channels and a sustained residual Na+ current
(Ahern et al., 2000). Moreover, S-nitrosylation of cardiac L-type Ca2+ channels using Snitrosoacetyl-penicillamine (SNAP), S-nitrosocysteine (SNC) or GSNO attenuates wholecell patch recording currents (Hu et al., 1997). The distinct impact of S-nitrosylation on a
variety of proteins and its effect on cardiac physiology make it essential to investigate.
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1.8 Summary and Rationale
SOCE is a major contributor to Ca2+ signalling and regulation. However, SOCE-mediated
intracellular Ca2+ elevation cannot occur without the activation of STIM1, which is
linked to its luminal domain Ca2+ sensitivity and stability. Although studies have revealed
that SOCE is vital in Ca2+ regulation within non-excitable cells (Molnar et al., 2012;
Redondo et al., 2006; Tojyo et al., 2014), the extent of its contribution to Ca2+
homeostasis in cardiomyocytes is less well-studied. Moreover, precisely how NO may
regulate the ER/SR Ca2+ sensor STIM1 and its influence on SOCE is still unknown. The
non-conserved N-terminal ends of STIMs are recognized to contribute to the differential
activation of STIM proteins (Stathopulos et al., 2009; Zhou et al., 2009), which is why I
postulate that the two partially conserved N-terminal Cys residues of STIM1 could have
important functional and mechanistic roles (Figure 1.2B). Interestingly, recent studies
suggest that STIM1 Cys49 and Cys56 undergo S-glutathionylation following oxidative
stress where Cys56 S-glutathionylated STIM1 becomes constitutively active and activates
SOCE regardless of luminal Ca2+ concentration (Hawkins et al., 2010). Due to their
susceptibility of oxidative stress, these Cys residues are also candidate sites for Snitrosylation. Previous studies have shown that S-nitrosylation can play an inhibitory role
on proteins including the fast and slow Na+ channels (Renganathan et al., 2002) as well
as NMDA receptors (Takahashi et al., 2007). Moreover, S-nitrosylation of tripartite
motif-containing protein 72 (TRIM72) was found to stabilize this protein, allow for
membrane repair and augment cardiomyocyte survival (Kohr et al., 2014). Importantly,
the lack of S-nitrosylation resulting from nNOS and eNOS deficiency has been shown to
cause cardiac hypertrophy (Barouch et al., 2003; Barouch et al., 2002). Thus,
modification of Cys49 and Cys56 residues in STIM1 via NO treatment would also be
expected to inhibit STIM1 activation by promoting its stabilization.
I propose that the stability and function of STIM1 may be regulated by S-nitrosylation of
its luminal domain at Cys residues 49 and 56. Thus, the aim of my study is to reveal the
effect of NO on STIM1 structure and stability in vitro and the downstream effects of
STIM1 S-nitrosylation on cardiomyocyte hypertrophy. Understanding the mechanisms by
which STIM1 S-nitrosylation contributes to Ca2+ signaling will enhance our
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comprehension of the SOCE pathway in health and disease. Specifically, identifying the
role of S-nitrosylated STIM1 in PE-induced cardiac hypertrophy will contribute to our
understanding of the pathogenic progression of cardiovascular disease and open exciting
avenues to novel treatments.

1.9 Hypothesis and aims
Hypothesis:
NO directly stabilizes and inhibits STIM1 by S-nitrosylation of the Cys49 and Cys56
thiol residues, thereby suppressing the Ca2+ sensitivity of STIM1. Furthermore, Snitrosylation of STIM1 mitigates PE-induced neonatal rat cardiomyocyte hypertrophy by
suppressing SOCE activation.

Aim 1: To elucidate the effect of S-nitrosylation on the stability, oligomerization,
structure and Ca2+ sensing function of STIM1 in vitro.
The luminal Ca2+ sensing region, STIM1 23-213, was cloned into a pET-28a vector,
expressed in BL-21 E. coli and purified using nickel-nitrilotriacetic acid agarose (NiNTA) beads in order to study this luminal STIM1 domain in an in vitro environment. The
purified STIM1 23-213 protein contains two thiol residues available for modification,
Cys49 and Cys56, which was treated with excess concentration of NO donors, GSNO
and sodium nitroprusside (SNP) to monitor the susceptibility and effect of Snitrosylation. Moreover, a structurally unresolved region at high resolution, STIM1 2457, located upstream of the EF-SAM domain and containing the Cys49 and Cys56
residues was subcloned into a pGEX-4T1 vector, expressed and purified before being Snitrosylated to reveal the structural changes to this peptide associated with the
modification.
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Aim 2: To examine how STIM1 S-nitrosylation is involved in mediating cardiomyocyte
hypertrophy.
Cardiomyocytes were isolated from 1-2 day old neonatal Sprague-Dawley rats and
incubated for 24 h on gelatin coated plates prior to treatment using PE to induce
hypertrophy. Various other reagents were also added to the cultured cardiomyocytes
following the PE treatment, including Orai1 inhibitor BTP2, STIM1 siRNA, NO donor
GSNO and ectopic expression of adenoviral nNOS, to investigate the phenotypic effect
of CRAC channel inhibition and NO on PE-induced cardiomyocyte hypertrophy. The
cells were then immunostained using a cardiac specific marker, α-actinin, and their
surface areas were measured after fluorescence microscopy imaging as an indicator of
hypertrophy.
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Chapter 2 Methods
2.1 Generation of STIM1 constructs and mutants
The luminal region (residues 23-213) of Homo sapiens STIM1 (NCBI accession
NP_003147.2) containing the Ca2+ sensing EF-SAM domain (residues 58-201) together
with the region containing the two Cys residues (Cys49 and Cys56) available for Snitrosylation (residues 23-57), was cloned into a pET-28a vector that has been used
previously for expressing the EF-SAM domain (residues 58-201) of STIM1 (Stathopulos
et al., 2006).
H. sapiens STIM1 residues 24-57 (NCBI accession NP_003147) was first subcloned
from pCMV6 STIM1 residues 1-685 template into pET-28a vector using NheI and XhoI
restriction sites. The DNA encoding the STIM1 24-57 peptide was then subcloned into
the pGEX-4T1 (GE Healthcare) vector using BamHI and EcoRI restriction sites.
Specifically, in order to obtain a STIM1 24-57 insert, a 150 μL PCR solution mixture was
first created using 112.5 μL dH2O, 30 μL 5× high fidelity (HF) Buffer, 0.75 μL 90 ng μL1

pCMV6 STIM1 template, 1.5 μL of each forward and reverse primer (Table 2.1), 3 μL

10 mM dNTPs and 0.75 Phusion DNA polymerase (Thermo Fisher Scientific). The 150
μL PCR solution was then divided into two PCR tubes with 75 μL in each and amplified
as described in Table 2.2. The final PCR product was electrophoresed at 125 V for 50
min on a 1.5% (w/v) agarose gel using a running buffer (TAE) that contains 0.5 × Tris,
acetic acid and ethylene diamine tetra acetic acid (EDTA). In order to estimate the size of
the PCR product (130 bp expected), 4 μL DNA ladder (GeneRuler 1kb Plus,
ThermoFisher) was run on a separate lane. The agarose gel was stained by submerging it
in 0.5 μg mL-1 ethidium bromide dissolved in water and shaking for 30 min at room
temperature. The STIM1 24-57 insert was visualized on the agarose gel under UV light
(302 nm), excised and transferred into an eppendorf tube. The DNA was extracted from
the gel using GeneFlow Gel/PCR kit according to the manufacturer’s protocol.
Sticky end overhangs were created by double digestion with BamHI and EcoRI on both
the STIM1 insert and pGEX-4TI vector. Digestion mixtures were prepared with 35 μL of
STIM1 insert, 4 μL Cut Smart Buffer and 0.5 μL of each restriction enzyme in one
microcentrifuge tube, and 11 μL pGEX-4TI vector, 2 μL Cut Smart Buffer, 1 μL of each
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restriction enzyme and 5 μL dH2O in the microcentrifuge tube. The digestion mixtures
were incubated overnight at 37 C. The digested DNA samples were separated on an
agarose gel, stained and observed under UV light as described above. The final BamHI
and EcoRI-digested STIM1 24-57 insert (102 bp after digestion) and pGEX-4TI vector
(4960 bp after digestion) were extracted from the agarose gel as described above.
Ligation of the digested insert into the digested pGEX-4TI vector was done by combining
4.5 μL dH2O, 2.5 μL pGEX-4TI vector, 10 μL STIM1 24-57 insert and 2 μL T4 DNA
ligation buffer, heating the mixture at 42 C for 2-3 min, chilling it on ice for 1 min and
adding 1 μL T4 DNA ligase. This ligation mixture was then placed in a water bath at 16
C for 16 hours. The ligation product was transformed through heat shock into DH5α E.
coli and selectively grown on ampicillin agar plates (100 g mL-1). Several bacterial
colonies were screened for the correct pGEX-4TI STIM1 24-57 vector by scraping each
colony with a pipette tip and placing it into an eppendorf tube that contains 20 μL of
dH2O. Afterwards, 5 μL of this colony-solubilized water was added into 10 μL 2× Taq
Frogga Mix, 0.5 μL pGEX forward primer, 0.5 μL pGEX reverse primer (Table 2.1) and
4 μL dH2O, and the entire mixture was subjected to PCR for 25 cycles (Table 2.2). The
PCR screen product was electrophoresed on 1.5% (w/v) agarose gel at 125 V for 50 min,
stained with ethidium bromide and colonies which showed the expected band size (~5000
bp) were grown in 5 mL Luria-Bertani broth (LB) containing 100 g mL-1 of ampicillin
overnight. The next day pGEX-4TI plasmids containing the STIM1 24-57 insert were
isolated from the liquid culture using the Presto Mini Plasmid kit (Geneaid) according to
the manufacturer guidelines.
A tyrosine (Tyr) residue was subsequently introduced by site-directed mutagenesis
immediately N-terminal to residue 24 to simplify protein detection via Coomassie
staining and facilitate UV at 280nm measurements for protein concentration
determination. Specifically, 0.5 μL of the forward and reverse primers (Table 2.1) were
each added to 14.15 μL dH2O, 4 μL 5× HF buffer, 0.4 μL DMSO, 0.25 μL undiluted
pGEX-4T1 STIM1 24-57 template DNA, 0.5 μL dNTPs and 0.2 μL Phusion DNA
polymerase (Thermo Fisher Scientific). The two PCR solutions containing either the
forward or reverse primer were first subjected to 10 PCR cycles under the parameters
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listed (Table 2.2); the resultant PCR products were immediately mixed together and the
final mixture was subjected to 25 more amplification cycles. The amplification product
was run alongside the same amount of input template DNA on a 1.5% (w/v) agarose gel
at 125 V for 50 min. A higher relative intensity of the PCR product under UV light (302
nm) compared to the input template was used as an indication of amplification success.
Subsequently, 0.75 μL (15 units) of DpnI restriction enzyme (New England BioLabs,
Inc.) was added to the remaining 25 μL of amplification product and incubated for 2 h 30
min at 37 C to digest the methylated template DNA. The digestion product was
transformed into DH5α E. coli and plated on an ampicillin LB plate. The next day,
colonies were grown in an overnight liquid culture and plasmids were isolated from the
liquid culture ~16 h later using the Presto Mini Plasmid kit (Geneaid).
In order to elucidate the importance of residues Trp121 and Lys122 in the luminal region
of STIM1, a double mutated construct pET-28a STIM1 23-213 Trp121Glu/Lys122Glu
was generated via the same mutagenic process as described above, using the primers and
amplification parameters in Tables 2.1 and 2.2.
All the subcloned and mutated constructs were made using High-Fidelity PCR
polymerase (Thermo Scientific, Inc.). All primers were synthesized by Sigma-Aldrich
and synthesized using the 0.025 μmol scale and cartridge purification (Table 2.1). The
isolated pET-28a STIM1 23-213 and pGEX-4TI STIM1 24-57 plasmids were sequenced
at Robart’s DNA Sequencing facility (Robarts Research Institute, Western University)
using the T7 reverse terminator primer and pGEX forward primer respectively (Table
2.1).
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Table 2.1. Oligonucleotide primers used in the research described in this thesis. (SigmaAldrich, St. Louis, MO)
Primer

Sequence
5’-GGCCAGGCTAGCAGCCATAGTCACAGTGAGAAG-3’

pET-28α
STIM1 24-57a

3’-GTTTCTCCTCGAGTTAGTGACACAGGGGCTTGTCAATTC-5’
5’-GGCCAGGGATCCAGCCATAGTCACAGTGAGAAG-3’

pGEX-4TI
STIM1 24-57a

3’-GTTTCTCGAATTCTTAGTGACACAGGGGCTTGTCAATTC-5’

pGEX-4TI

5’-CTGGTTCCGCGTGGATCCTATAGCCATAGTCACAGTGAGAAG-3’

STIM1 24-57
Y-insertb

3’-CTTCTCACTGTGACTATGGCTATAGGATCCACGCGGAACCAG-5’

pET-28α
STIM1 23-213

5’-CATCAGCGTGGAGGACCTGGAGGAGGCATGGAAGTCATCAG-3’

Trp121Glu/
Lys122Gluc

3’-CTGATGACTTCCATGCCTCCTCCAGGTCCTCCACGCTGATG-5’

T7 terminatord

5’-GCTAGTTATTGCTCAGCGG-3’

pGEX
forwardd,e

5’- GGGCTGGCAAGCCACGTTTGGTG-3’

pGEX reversee

3’- CCGGGAGCTGCATGTGTCAGAGG-5’

a

Subcloning primers for STIM1 24-57

b

Mutagenesis primer for pGEX-4TI STIM1 24-57

c

Mutagenesis primer for pET-28a STIM1 23-213

d
e

Sequencing primer

Screening primers for pGEX-4TI STIM1 24-57
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Table 2.2. PCR amplification parameters on LifeECO (Bioer).
pET-28a

pGEX-4TI

pGEX-4TI

pGEX-4TI

STIM1 24-57

STIM1 24-57

STIM1 24-57 STIM1 23-213

screening

subcloning

Y-insert

Trp121Glu/

mutagenesis

Lys122Glu
mutagenesis

25 Cycles

35 Cycles

10 Cycles

10 Cycles

+ 25 Cycles

+ 25 Cycles

Temp

Time

Temp

Time

Temp

Time

Temp

Time

(C)

(sec)

(C)

(sec)

(C)

(sec)

(C)

(sec)

98

30

98

30

98

35

98

35

98

10

98

10

98

10

98

10

Annealing

54

30

54

30

53

30

54

30

Extension

72

30

72

30

72

180

72

180

Final Extension

72

30

72

30

72

330

72

330

Storage

4



4



4



4



Initial Denaturation
Denatura# Cycles

tion
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2.2 Protein expression and purification
2.2.1 pET-28a STIM1 23-213 wildtype and mutants
Transformants of pET-28a STIM1 23-213 were selected by using kanamycin LB agar
plates where incorporation of the gene construct into BL21(DE3) E. coli is necessary for
those bacteria cells to form viable colonies. Individual colonies were picked for 65 mL
starter liquid cultures in a 500 mL flask. This 65 mL of starter culture was used for 6× 1
L LB expression containing 60 g mL-1 kanamycin using 6× 4 L flasks. The cultures
were grown at 37 C with 190 rpm constant shaking. The cultures were grown until the
optical density at 600 nm (OD600) was in the ~0.6-0.8 range, at which point, 200 μM of
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce protein expression.
Upon IPTG addition, the temperature was dropped to 25 C. After ~4 h of growth at 25
C and 190 rpm, the bacterial cells were collected using a JA10 rotor in a J2-21M
Induction drive centrifuge (Beckman, Inc.) with the parameters set to 9,300 ×g, 4 C for
30 min. The pelleted cells were stored at -80 C until purification. The 200 μM IPTG
concentration, 25 C expression temperature and 4 h growth period were determined by
varying these parameters in an incrementing fashion until the optimal conditions that
produced the most proteins with least degradation were found.
The STIM1 23-213 protein was purified by first manually homogenizing 7-8 mL of wet
bacterial cell pellet collected from 2 L of LB culture in 40 mL of 6 M guanidine
hydrochloride, 20 mM Tris-HCl (pH 8) and 5 mM β-mercaptoethanol (BME) with a
motorized 10 mL transfer pipette. The homogenized mixture was rotated in a
hybridization oven at room temperature for 90 min to release the protein from inclusion
bodies, and then centrifuged using a JA20 rotor in a J2-21M Induction drive centrifuge at
12,100 ×g, 8 C for 40 min to obtain the protein supernatant and remove insoluble debris.
The clarified lysate containing the solubilized protein was incubated subsequently with
450 μL of 50% (v/v) nickel-nitrilotriacetic acid (Ni-NTA) agarose bead slurry (HisPur,
ThermoFisher Scientific) in the hybridization oven and rotated for another 90 min at
room temperature to bind the hexahistidine (6×His)-tag of the protein to the beads. The
STIM1 23-213 protein bound to the beads was then retained in a gravity flow protein
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purification column, washed three times with 10 mL of 6 M Urea, 20 mM Tris-HCl (pH
8) and 5 mM BME, eluted seven times with 2 mL of 6 M Urea, 20 mM Tris-HCl (pH 8),
5 mM BME and 300 mM imidazole following 2 min incubation between each elution.
After the presence of the protein in the elution fractions was confirmed on a Coomassie
stained SDS-PAGE gel (Figure 2.1A), the elutions that contain the protein of interest
were pooled together into a 3,500 Da molecular weight cutoff dialysis membrane
(BioDesign Inc.) and placed into the 1 L refolding buffer [20 mM Tris-HCl (pH 8), 300
mM NaCl, 1 mM dithiothreitol (DTT) and 5 mM CaCl2]. A magnetic stir bar was used to
ensure homogeneous exchange between the unfolding and folding buffers overnight at 4
C. Following ~24 h of refolding, ~1 U of thrombin (BioPharm Laboratories, Inc.) per
mg of protein was added into the dialysis membrane bag and placed back in the refolding
buffer for another ~24 h. The efficiency of thrombin cleavage was elucidated by running
a sample of the protein aliquot before and after the addition of thrombin on an SDSPAGE gel (Figure 2.1B). Size-exclusion chromatography (SEC) was performed to further
separate STIM1 23-213 from contaminant proteins expressed in the cell (Figure 2.2).
STIM1 23-213 wildtype protein concentration was estimated using a ε280 nm = 1.2418 mg
mL-1 cm-1 extinction coefficient. Approximately 4 mg of protein was obtained from each
2 L LB culture pellet.
The single mutant STIM1 23-213 Cys49Ser and STIM1 23-213 Cys56Ser as well as the
double

mutant

STIM1

23-213

Cys49Ser/Cys56Ser

and

STIM1

23-213

Trp121Glu/Lys122Glu proteins were also expressed and purified the same way as the
wildtype protein with similar yields, except reducing agents BME and DTT were not
added while purifying STIM1 23-213 Cys49Ser/Cys56Ser since there was no possibility
of disulfide bond formation. The STIM1 23-213 Cys49Ser, STIM1 23-213 Cys56Ser,
STIM1 23-213 Cys49Ser/Cys56Ser and STIM1 23-213 Trp121Glu/Lys122Glu protein
concentrations were estimated using ε280 nm = 1.2427 mg mL-1 cm-1, 1.2427 mg mL-1 cm-1,
1.2436 mg mL-1 cm-1 and 0.9909 mg mL-1 cm-1 extinction coefficients, respectively.
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2.2.2 pGEX-4T1 STIM1 24-57
The pGEX-4TI STIM1 24-57 construct containing the Tyr insert mutation immediately
upstream of residue 24 was transformed by heat shock into BL21(DE3) E. coli cells as
described above for the pET-28a STIM1 23-213, except 100 g mL-1 ampicillin was used
as the selection marker. Colonies were picked and expressed in 30 mL LB in a 250 mL
Erlenmeyer flask containing 100 g mL-1 ampicillin at 37 C and 190 rpm overnight. The
next day, 10 mL of this starter culture was added to 1 L of LB contained in a 4 L
Erlenmeyer flask and supplemented with ampicillin at 100 g mL-1. The culture was
grown at 37 °C and 190 rpm until the OD600 reached ~0.6-0.8. Subsequently, 300 μM
IPTG was added and the expression temperature was dropped to 30 C. The cells were
cultured for ~4 h before being collected as described above.
The wet cell pellets were purified essentially as described in the manufacturer’s
glutathione-S-transferase (GST) Sepharose protocol (Genescript). Specifically, the 5 mL
cell pellet obtained from a 2 L LB expression was resuspended in 45 mL wash buffer
containing 1× PBS and 1 mM DTT. The bacterial mixture was then sonicated on ice at 40
% power using the Fisher Sonic Dismembrator Model 150 for 10 min in 3 sec on and 3
sec off cycles. After the addition of 0.2% (v/v) triton x-100, the resultant mixture was
rotated in the cold room for 90 min to release the STIM1 24-57 peptide into solution and
centrifuged at 12,100 ×g, 8 C for 40 min using a JA20 rotor in a J2-21M Induction drive
to separate the insoluble cell debris. Approximately 1 mL of 50 % (v/v) GST beads in 10
% ethanol was added to 30 mL of wash buffer that contains 1× PBS and 1 mM DTT and
the excess liquid was poured off following centrifugation at 2000 ×g for 5 min. The
washed GST beads were then added to the protein clarified lysate and rotated in the cold
room for another 90 min. The STIM1 24-57 peptide bound to the GST beads was retained
using a gravity flow purification column and washed with 3× 10 mL wash buffer that
contains 1× PBS and 1 mM DTT. Sixteen mL of protein folding buffer containing 20
mM TRIS, 150 mM NaCl, 1 mM DTT (pH 7.5) and thrombin (~ 5 units mg-1 of total
protein) were added to the peptide bound GST beads. After rocking in the cold room
overnight, the STIM1 24-57 peptide was liberated from the GST bound to the resin by
thrombin and eluted from the column. More peptide was collected by washing the GST
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beads with 3× 1 mL protein folding buffer with the components described above. The
pre-thrombin solution, elution and three washes were run on a gel to verify the presence
of the peptide in the elution and typically in the first wash. The samples containing the
STIM1 24-57 peptide were then pooled and further purified by SEC (Figure 2.3). STIM1
24-57 peptide concentration was estimated using a ε280

nm

= 0.3296 mg mL-1 cm-1

extinction coefficient. Approximately 5 mg of protein was obtained from each 2 L LB
culture pellet. Due to the aberrant migration of the protein on SDS-PAGE gel (Figure
2.3), a sample of the purified protein was analyzed by electrospray ionization mass
spectroscopy to confirm the identity of the purified protein. The theoretical monomeric
mass of the STIM1 24-57 construct was calculated to be 3,719.92 Da; the mass
spectrometry measured mass was 3,720.09 Da, confirming the identity of the purified
peptide as STIM1 24-57 (Figure 2.4).
For NMR experiments, the STIM1 24-57 peptide was uniformly
15

N and

13

15

N-labelled or double

C-labelled using M9 medium containing 42 mM Na2HPO4, 22 mM KH2PO4

and 8.6 mM NaCl (pH 7.4) as well as additives that were filtered through a 0.2 m
syringe filter (Millipore). The additives included 0.2 % (w/v) D-glucose or D-glucose13

C, 100 M CaCl2, 50 M thiamine, 1 mM MgSO4, 1 g ml-1 biotin and 1 mg ml-1 15N-

NH4Cl. First, a 30 mL starter liquid culture was grown in LB overnight for ~16 h at 37 C
and 190 rpm. The bacterial liquid culture was centrifuged at 2,400 ×g for 15 min,
decanted to remove the LB medium, resuspended in 10 mL of M9 medium and
transferred into the 1L M9 expression medium containing all the aforementioned
additives. The rest of the expression protocol including growth temperature, time, IPTG
concentration, collection and purification were the same as the non-labelled sample
described above with similar yields.
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2.2.3 pET-28a STIM1 58-201 (EF-SAM)
pET-28a STIM1 58-201 (EF-SAM) was expressed in BL21(DE3) E. coli using LB that
contains 60 g mL-1 kanamycin at 37 C and 190 rpm. A similar overnight starter culture
approach was applied here, as described for STIM1 23-213. After OD600 reached ~0.60.8, 200 μM IPTG was added and the temperature was dropped to 22 C with constant
shaking at 190 rpm for an additional ~16 h. The cells were collected as described above
and the pellets were stored at -80 C until purification. Purification was performed using
Ni-NTA agarose beads as described for STIM1 23-213 with the following modifications.
The STIM1 58-201 (EF-SAM) protein bound to the beads was retained in a gravity flow
column, washed three times with 10 mL of wash buffer that contains 6 M Urea and 20
mM Tris-HCl (pH 8) as well as eluted seven times with 2 mL of elution buffer that
contains 6 M Urea, 20 mM Tris-HCl (pH 8) and 300 mM imidazole following 2 min
incubation between elutions. The 5 mM BME was not present in the wash and elution
buffers because there are no Cys residues that need to be reduced in the EF-SAM protein
segment. The elutions that contain the protein of interest were pooled together into a
3,500 Da molecular weight cutoff dialysis membrane (BioDesign Inc.) and placed into
the 1 L refolding buffer with 20 mM Tris-HCl (pH 8), 150 mM NaCl and 5 mM CaCl2.
After ~24 h of refolding at 4 C aided by the use of a magnetic stir bar, ~1 U of thrombin
(BioPharm Laboratories, Inc.) per mg of protein was added into the dialysis membrane
and placed back into the refolding buffer for an additional ~24 h to cleave off the 6×His
tag. After thrombin digestion, anion-exchange chromatography (AEC) was performed as
an additional purification step. A 1 mL DEAE FF column (GE Healthcare) was used for
AEC, and this column was first equilibrated with a no salt buffer containing only 20 mM
Tris-HCl (pH 8) and 5 mM CaCl2. Proteins were then slowly bound onto the column at a
rate of 1 mL min-1 after being diluted with the no salt buffer to a final ~15 mM NaCl
concentration and filtered through a 0.45 μM syringe filter. During the 30 mL elution
stage, the salt concentration in the column was gradually increased from 0 to 600 mM
NaCl at 1 mL min-1 using a high salt buffer that contains 1 mM NaCl, 20 mM Tris-HCl
(pH 8) and 5 mM CaCl2. A representative Coomassie-blue stained gel of elutions is
shown in Figure 2.5. The elutions containing the protein of interest were pooled and
dialyzed into the specific experimental buffer that typically contains 20 mM Tris-HCl
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(pH 8), 50 mM NaCl and 5 mM CaCl2. EF-SAM protein concentration was estimated
using a ε280 nm = 1.6062 mg mL-1 cm-1 extinction coefficient. Approximately 0.5 mg of
protein was obtained from each 2 L LB culture pellet.
15

N-labelled STIM1 58-201 (EF-SAM) protein expression was done via the same process

as the

15

N-labelled STIM1 24-57 peptide except using the expression parameters

described above for EF-SAM (~16 h expression at 22 C). Protein purification was done
through the same process as the non-labelled EF-SAM protein with similar yields.
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2.3 S-Nitrosylation of STIM1
The proteins of interest (i.e. STIM1 23-213 wildtype, single mutants Cys49Ser and
Cys56Ser, double mutants Cys49Ser/Cys56Ser and Trp121Glu/Lys122Glu, STIM1 24-57
with Tyr insert) were exchanged into a buffer containing excess NO donors (1 mM
GSNO or 2 mM SNP) by ultrafiltration. Essentially, a 20×20×20-fold buffer exchange
was done at 2,500 ×g, 4 C, using centrifugal concentrators (Vivaspin 20) with 10,000 or
3,000 MWCO (Sartorius, Inc.) for STIM1 23-213 and STIM1 24-57, respectively.
The ~500 mM stock GSNO was synthesized by dissolving 1.54 g of reduced glutathione
in 5.9 mL of 570 mM HCl. This acidic glutathione solution was stirred vigorously while
1 mL of 5 M NaNO2 was added, and this mixture was stirred for an additional 5 min in
the dark. The final GSNO stock solution was adjusted to pH 6 using 1 M NaOH and
brought to a final volume of 10 mL using dH2O. The concentration of GSNO was
measured using a spectrophotometer set to 335 nm wavelength and an extinction
coefficient of 0.92 mM-1 cm-1 (Broniowska et al., 2013). The 500×, 750× and 1000×
diluted GSNO samples were used for concentration measurements to accurately assess
the GSNO stock concentration. The ~500 mM stock GSNO was stored in 1 mL aliquots
at -80 C. Different S-nitrosylation buffer components were used depending on the
specifics of the experiment conducted, details of which will be described below.

2.4 Far-UV circular dichroism (CD) spectroscopy
The STIM1 23-213 wildtype, single and double mutant protein samples were transferred
into the selective buffers using a centrifugal concentrator (Vivaspin 20 with 10,000
MWCO; Sartorius, Inc.) essentially through a 20×20×20-fold buffer exchange. The
control buffer contained 1 mM DTT, 10 mM TRIS-HCl and 5 mM CaCl2 (pH 7.4) while
the experimental buffer contained 1 mM GSNO or 2 mM SNP, 10 mM TRIS-HCl and 5
mM CaCl2 (pH 7.4). To prepare the protein samples for experiments under the Ca2+depleted condition, 50 mM EDTA was added the day prior to the buffer exchange
process and the sample was incubated for ~ 16 h at 4 C. The exchange was subsequently
performed in the absence of Ca2+, as described above. UV absorbance at 280 nm (A280)
was used to estimate protein concentration and 275 μL of 0.5 mg/mL protein was used in
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each experiment. Far-UV CD spectra and thermal melt analyses were performed to
characterize the protein secondary structure and thermal stability, respectively. Data were
acquired on a Jasco J-815 CD Spectrometer (Jasco Inc.) with a Jasco PTC-423S
temperature controller. Spectra were acquired at 20 C from 240 nm to 200 nm in 1 nm
increments (20 nm min-1) by using a 0.1 cm pathlength quartz cuvette, an 8-s averaging
time, an average of 3 accumulations and 1 nm bandwidth. Moreover, the protein spectra
were corrected for buffer contributions (10 mM TRIS  5 mM CaCl2, pH = 7.4).
Thermal melts were acquired by monitoring the change in the 225 nm CD signal as a
function of temperature in 0.1 cm pathlength quartz cuvettes, an 8-s averaging time, 1 nm
bandwidth and a 1 °C min-1 scan rate. The apparent midpoints of temperature
denaturation (Tm) were extracted from the thermal melts using Boltzmann sigmoidal fits
in GraphPad, where the Boltzman sigmoid equation used was:

1

10

∙

where Y = change in CD signal,
Min = minimum CD signal (folded baseline),
Max = maximum CD signal (unfolded baseline),
Tm = temperature of denaturation,
and

X = temperature.

2.5 Ca2+ binding
It has been previously demonstrated that EF-SAM Ca2+ binding affinity estimates using
intrinsic fluorescence changes are similar to direct binding estimates using 45Ca2+ assays
(Stathopulos et al., 2006). After overnight incubation in 50 mM EDTA, wildtype STIM1
23-213 protein was exchanged into a buffer containing 20 mM TRIS, 150 mM NaCl, and
1 mM DTT or 1 mM GSNO (pH 7.4) via the same ultrafiltration process described
above. Fluorescence readings at 37 C were obtained on a Cary Eclipse
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spectrofluorimeter (Varian/Agilent, Inc) using 600 μL of 0.1 mg mL-1 protein in 600 μL
quartz cuvettes. The intrinsic protein fluorescence emission spectra were measured from
300 nm to 450 nm using an excitation wavelength of 280 nm. The excitation and
emission slit widths were 5 nm and 10 nm, respectively, and the photomultiplier (PMT)
detector was set at 600 V. The equilibrium dissociation constant (Kd) was estimated from
the change in intrinsic fluorescence using a one site-binding model which takes into
account protein concentration:
,

4

∙

]

where Kd = equilibrium dissociation constant,
P = free protein concentration,
Ca = total Ca2+ concentration,
PCa = Ca2+ bound protein concentration,
and

Ptot = total protein concentration.

2.6 8-Anilinonaphthalene-1-sulfonic acid (ANS) binding
The relative levels of solvent-exposed hydrophobicity were assessed via extrinsic
fluorescence of ANS on a Cary Eclipse spectrofluorimeter (Varian/Agilent, Inc).
Wildtype and double mutant Cys49Ser/Cys56Ser STIM1 23-213 protein samples were Snitrosylated as described above via ultrafiltration. The control and experimental buffers
contained 20 mM TRIS, 150 mM NaCl with and without Ca2+ as well as 1 mM DTT or 1
mM GSNO (pH 7.4). UV absorbance at 280 nm (A280) was used to estimate protein
concentration and 600 μL of 0.143 mg mL-1 protein was loaded in 600 μL quartz cuvettes
for each experiment. The extrinsic ANS-induced fluorescence (excitation wavelength, λex
= 372 nm) was measured from 400 nm to 600 nm at 37 C using an excitation
wavelength of 372 nm. Excitation and emission slit widths were set at 10 nm and 20 nm,
respectively, while the PMT detector was set at 700 V.
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2.7 Dynamic light scattering (DLS)
Wildtype and double mutant Cys49Ser/Cys56Ser and Trp121Glu/Tyr122Glu STIM1 23213 proteins were exchanged into their experimental buffers via ultrafiltration as
described above. The control and experimental buffers contained 20 mM TRIS, 150 mM
NaCl, and 1 mM DTT or 1 mM GSNO (pH 7.4). A final concentration of 0.46 mg mL-1
was obtained and proteins were centrifuged at 12,000 ×g before a 5 μL aliquot was
loaded into a dust-free quartz MicroCuvette (JC501) for light scattering measurements on
a DynaPro Nanostar (Wyatt Technology). The control and experimental buffers that were
originally used for ultrafiltration were first loaded into the quartz cuvette and a reading
was taken after 5 min equilibration to ensure that the cuvette was dust-free. Experiments
were conducted at 37 C, where the cuvette containing the protein of interest was allowed
equilibrate for 5 min before 10 consecutive acquisitions were recorded per sample with
each acquisition averaged for 5 seconds. The regularization for polydisperse solutions
using the accompanying instrumental software was performed with the low and high cutoffs for the hydrodynamic size set to 1.5 nm and 150 nm respectively.

2.8 Solution nuclear magnetic resonance (NMR) spectroscopy
2.8.1 STIM1 24-57 backbone assignment and structure
Solution NMR spectroscopy experiments were performed using a 600 MHz Inova NMR
spectrometer (Varian/Aglilent, Inc.) equipped with a cryogenic, triple HCN resonance
probe. A set of pilot experiments were first conducted to determine the optimal
temperature and salt concentration for the STIM1 24-57 peptide. Approximately 200 μM
of 15N single-labelled STIM1 24-57 peptide was exchanged into a buffer containing 150
mM or 300 mM NaCl, 20 mM TRIS, 1 mM DTT (pH 7.5) via ultrafiltration. Afterwards,
1

H-15N heteronuclear single quantum coherence (HSQC) experiments (Farrow et al.,

1994; Kay et al., 1992) were conducted at varying temperatures and NaCl concentrations.
Since most of the crosspeaks became visible under lower NaCl concentration and
temperature conditions, the optimal experimental condition was chosen to be 50 mM
NaCl at 15 C. Wilmad 5 mm frequency matched NMR tubes were used for all the
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experiments. Moreover, 60 μM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) and 10
% D2O (v/v) were added to each NMR sample.
To determine the backbone chemical shift assignments and associated secondary
structure of the STIM1 24-57 peptide, 600 μL experimental sample was prepared by
mixing ~200 μM of

15

N,

13

C double-labelled STIM1 24-57 peptide in a buffer that

contains 20 mM TRIS, 50 mM NaCl and 2 mM GSNO or 2 mM DTT (pH = 7.4) with 60
μM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) and 10 % D2O (v/v). Sequential
backbone assignments were made using

1

H-15N HSQC, HNCACB and HNCO

experiments (Grzesiek and Bax, 1993; Wang et al., 1994). The parameters for HNCACB
were 5000 Hz 1H sweep width, 9600 Hz 13C sweep width, 1700 Hz 15N sweep width, 48
transients, 44 increments in the

13

C dimension and 24 increments in the

The parameters for HNCO were 5000 Hz 1H sweep width, 3770 Hz
1700 Hz

15

N sweep width, 20 transients, 20 increments in the

13

13

15

N dimension.

C sweep width,

C dimension and 24

increments in the 15N dimension.
The two- and three-dimensional spectra were processed, and resonance assignments were
made using NMRPipe and XEASY, respectively (Bartels et al., 1995; Delaglio et al.,
1995). The efficiency and structural changes associated with S-nitrosylation were
assessed based on the chemical shift perturbations calculated from the backbone amides
as well as the Cα and Cβ carbons. The chemical shift perturbations (CSP) of the STIM1
24-57 peptide were calculated using the following equations:
Alpha carbon: C CSP
Beta carbon: C CSP

ΔδC
ΔδC

Amide backbone CSP: total H N CSP

ΔδH

0.14 ΔδN
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2.8.2 Paramagnetic relaxation enhancement (PRE) spectroscopy
In order to nitroxide spin label the STIM1 24-57 protein, 0.116 mg of

15

N labelled

STIM1 24-57 peptide was first dialyzed twice into N-morpholino propanesulfonic acid
(MOPS) buffer containing 20 mM MOPS, 50 mM NaCl and 0.1 mM TCEP-HCl (pH
8.3). Subsequently, 4 mM methanethiosulfonate (MTSL) was added to the peptide and
this sample was incubated in the dark at room temperature for 2 hours. Finally, the
nitroxide spin labelled peptide was dialyzed twice into the NMR buffer containing 20
mM TRIS, 50 mM NaCl and 5 mM CaCl2 (pH 7.4) to remove the unreacted label and
leave the sample in the experimental buffer. An 1H-15N-HSQC spectrum was acquired on
the 600 MHz Inova NMR spectrometer (Varian/Agilent, Inc.) with a 5000 Hz 1H sweep
width, 1700 Hz 15N sweep width, 16 transients and 64 increments in the 15N dimension.
The 600 μL sample contained ~50 μM nitroxide spin -15N labelled STIM1 24-57 peptide,
60 μM DSS and 10 % D2O (v/v). The 1H-15N-HSQC exhibited very few peaks due to the
peak broadening effect by the spin label. A second HSQC spectrum was obtained using
identical parameters following the addition of 15 mM DTT to remove the nitroxide spin
label from the Cys residues. The DTT treatment restored a majority of the crosspeaks,
thereby validating the spin label methodology (Figure 2.6).
To map the interacting site of the STIM1 24-57 peptide on EF-SAM, ~0.25 mg of
unlabelled STIM1 24-57 peptide was nitroxide spin-labelled as described above and
finally dialyzed into the NMR buffer that contains 20 mM TRIS, 50 mM NaCl and 5 mM
CaCl2 (pH 7.4).

15

N single-labelled EF-SAM protein was also dialyzed into the NMR

buffer containing 20 mM TRIS, 50 mM NaCl and 5 mM CaCl2 (pH 7.4) for these
experiments. The 107 μM nitroxide spin labelled STIM1 24-57 peptide and 46 μM

15

N

single-labelled EF-SAM protein samples were mixed together, and an HSQC spectrum
monitoring the binding sites of the peptide on EF-SAM as suppressed amide resonances
was obtained. A second HSQC spectrum was obtained following the addition of 15 mM
DTT which removed the nitroxide spin label from the Cys residues by reduction, in order
to ascertain amide reference intensities. The 1H-15N-HSQC parameters employed for
these PRE experiments were 8000 Hz 1H sweep width, 1800 Hz
transients and 64 increments in the 15N dimension.

15

N sweep width, 32
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2.9 Urea Denaturation
Wildtype and double mutant Cys49Ser/Cys56Ser STIM1 23-213 protein samples were
exchanged into a buffer containing 5 mM CaCl2, 150 mM NaCl, 20 mM TRIS (pH 7.4)
as well as 1 mM DTT or 1 mM GSNO by ultrafiltration. Samples were prepared with
urea concentrations ranging from 0 to 5 M, while protein concentration was kept constant
at 5 μM. After incubation in the water bath overnight at 25 C, intrinsic fluorescence
readings were taken for each sample. The excitation wavelength was set at 280 nm which
excites the aromatic residues Phe, Tyr and Trp, and fluorescence emission spectra were
acquired between 300-450 nm. Chemical denaturation curves were constructed from the
change in fluorescence emission intensity at 339 nm or 337 nm versus urea concentration
for the Ca2+ loaded and Ca2+ depleted conditions, respectively. Thermodynamic stability
parameters were extracted from the chemical denaturation curves by non-linear
regression fitting of the data to a two state, folded to unfolded model. The denaturant
dependence of Gibbs free energy (m-value) and Gibbs free energy of unfolding in the
absence of denaturant (GH2O) were fit using the linear extrapolation method (Pace,
1986) according to the following equations:
ΔG = -RT ln K = ΔGH2O - m×[urea], where R is the universal gas constant, T is
temperature in Kelvin and K is the equilibrium constant of two state unfolding. K is
related to the fraction of unfolded (FU) protein as
F

K
1

K

, and thus FU can be solved by rearranging ΔG = -RT ln K as
F

ΔG
RT
ΔG
exp
RT

exp
1

, where ΔG = ΔGH2O – m×[urea]
The midpoint of chemical denaturation, Cmid, was calculated from
ΔG

52

2.10 Cardiomyocyte Culture
2.10.1 Cardiomyocyte isolation and culture
Neonatal (1-2 day old) Sprague Dawley rat hearts were removed into cool D-hanks
balance solution, washed and minced aseptically. The ventricular tissue was transferred
into 10 μg mL-1 Liberase TH (Roche Cat. #05401135001) in D-hanks solution, digested
for 3× 10 min and collected by centrifugation at 500 ×g for 5 min. The collected cells
were resuspended to 1 million mL-1 in culture medium containing a 2:1 mixture of
DMEM and M199 as well as 10% FBS and 1% penicillin streptomycin (PS). After 60
min pre-plate on a 35 nm dish in the CO2 incubator, the cells were filtered and seeded in
1 % gelatin coated plates.

2.10.2 Experimental treatments
Following 24 h of growth at 37 C, ventricular cardiomyocyte cultures in selective wells
were treated with 50 μM PE for 2 days to induce the hypertrophic phenotype. For
particular wells that need to be treated with 10 nM of control siRNA or 10 nM STIM1
siRNA, the PE treatment was delayed until 24 h after these RNA oligos were
incorporated into the cardiomyocytes using the jetPRIME transfection reagent (Polyplus
transfection) according to the manufacture’s protocol. The adenoviral nNOS and
adenoviral GFP treatments (moi = 10) were also administered 24 h prior to PE treatment,
while the 5 μM BTP2 and 100 μM GSNO treatments were applied with PE. The culture
medium was exchanged every 24 h and the necessary treatments were supplemented into
selective wells.

2.10.3 Cardiomyocyte staining and imaging
The cultured ventricular cardiomyocytes were first washed using PBS, which is followed
by a 30 min fixation period using 4 % paraformaldehyde (PFA). After another PBS wash,
the cells were permeabilized by the 0.1 % triton x-100 in PBS treatment for 8 min. 1 %
BSA in PBS was used to block the permeabilized cells for 1 h. This was followed by an
overnight incubation using 1:1000 diluted 1 anti-α actinin antibody produced in mouse
(Sigma-Aldrich). The cells were washed again using PBS and incubated with 1:1000

53

diluted 2 anti-mouse antibody for 1 h. After a short 2-3 min incubation period with
1:1000 diluted Hoechst stain, the cells were washed using PBS and the coverslips were
mounted using Dako fluorescence mounting medium onto the slides and stored at 4 C.
Following fluorescence microscopy imaging of ~ 100 cardiomyocytes from ~4 separate
cultures per treatment group, AxioVision program was used to outline the cell borders
and estimate the cardiomyocyte size.

2.11 Statistical analysis
Statistical analyses were performed using an unpaired t-test when comparing between
two independent groups, whereas one-way ANOVA followed by Tukey’s post-hoc test
was used to compare more than two treatment groups. Tukey’s multiple comparison
analysis was used as opposed to other methods because of its conservative estimate of the
α-value, which decreases the likelihood of obtaining a false positive significance. Other
tests such as the Newman-Keuls method are less stringent and can reach statistical
significance more easily (McHugh, 2011). Since the effect of S-nitrosylation on STIM1
and its downstream effect on PE-induced cardiomyocyte hypertrophy is fairly uncertain, I
used the Tukey’s post-hoc test in order to obtain statistics on the differences among all
the different groups.
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Chapter 3

Results

3.1 The α-helicity of STIM1 23-213 is attenuated upon Ca2+
depletion.
The Ca2+-depletion induced loss in STIM1 EF-SAM -helicity and stability is a hallmark
of SOCE initiation. Using far-UV CD spectra obtained from 240 nm to 200 nm, I
examined the secondary structure of wildtype STIM1 23-213 protein in buffers
containing 10 mM TRIS-HCl (pH 7.4) and 1 mM DTT with or without 5 mM CaCl2
(Figure 3.1). Spectra were corrected for buffer contributions. As expected, this luminal
region of STIM1 encompassing the EF-SAM domain (residues 58-201) together with the
region containing the two conserved Cys residues (Cys49 and Cys56) showed a typical αhelical spectrum with two characteristic minima at around 225 nm and 208 nm.
Moreover, I observed an attenuation of α-helicity in the protein samples depleted of Ca2+
as indicated by the reduction in the intensity of the negative ellipticity at the 208 and 225
nm. The effects of S-nitrosylation were not amenable to investigation by acquisition of
far-UV-CD spectra because below ~210 nm wavelength, the high tension (HT) of the
samples rose above 800 V, thereby distorting the spectra and making the reading
unreliable.
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3.2 S-Nitrosylation increases the thermal stability of STIM1
23-213 wildtype protein.
While monitoring changes in secondary structure caused by S-nitrosylation by far-UV
CD was not possible due to high absorbance of the NO donor containing buffer at
wavelengths below ~210 nm, assessing changes in thermal stability due to S-nitrosylation
was possible since the high tension does not rise above 800 V at 225 nm in the presence
of GSNO or SNP over the temperature range monitored. Three treatment groups were
present in this experiment: 1 mM DTT as the control, 1 mM GSNO and 2 mM SNP as
the NO donors which were introduced by ultrafiltration. The apparent denaturation
midpoints (Tm) for each treatment group (Table 3.1) were obtained as an indication of
protein stability. A systematic shift to the right was observed for the thermal melt curves
of wild type proteins with NO donors GSNO or SNP compared to the control monitored
at 225 nm (Figure 3.2A and 3.2C). This approach of using excess NO donors to Snitrosylate proteins in vitro has been previously used (Albertos et al., 2015; Ji et al.,
1999) due to the labile nature of the modification which is readily reversible upon
removal of the NO donor. Boltzmann sigmoidal fits were used to estimate the apparent
Tm where a higher apparent Tm is indicative of a more stable protein sample (Table 3.1).
The apparent Tm of wildtype STIM1 23-213 in the Ca2+-loaded state was significantly
increased by ~ 2 °C in the presence of either excess GSNO or SNP (Figure 3.2A and
3.2B). Remarkably, the increase in apparent Tm was much more pronounced under Ca2+
depletion conditions (i.e. ΔTm = ~+4C, *p < 0.05), indicating a greater stabilization of
luminal STIM1 23-213 by the presence of excess NO donors in the absence of Ca2+
(Figure 3.2C and 3.2D) which is the state that initiates STIM1 oligomerization for SOCE
activation. Importantly, double mutant STIM1 with both native Cys replaced by Ser (i.e.
Cys49Ser/Cys56Ser) (Figure 3.3A and 3.3B) did not undergo stabilization, suggesting a
Cys-specific response. Surprisingly, however, single mutant versions of STIM1 23-213
with one of the Cys replaced by Ser (Figure 3.3C-F) did not exhibit stabilization.
Collectively, these data demonstrated that the STIM1 luminal domain stability is
enhanced in the presence of excess NO. Furthermore, the increase in stability is
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detectable by thermal denaturation when both Cys49 and Cys56 are present. Stabilization
of

the

STIM1

luminal

domains

would

suppress

the

destabilization-coupled

oligomerization event which triggers SOCE activation, suggesting a mechanistic basis for
nNOS-mediated SOCE inhibition in cardiomyocytes.
Table 3.1 Apparent denaturation midpoint (Tm) of STIM1 23-213 wildtype, double and
single mutants under conditions with or without Ca2+ and/or S-nitrosylation.
STIM1 23-213

Condition

Apparent Tm (C)
(Mean  SEM)

Ca2+ loaded
Wildtype

Unmodified/+1mM DTT (n = 4)

62.49  0.49

S-Nitrosylated/+1mM GSNO (n = 3)

64.26  0.31*

S-Nitrosylated/+2mM SNP (n = 3)

64.46  0.07*

Ca2+ depleted
Wildtype

Unmodified/+1mM DTT (n = 5)

41.72  0.57

S-Nitrosylated/+1mM GSNO (n = 4)

45.08  0.88*

S-Nitrosylated/+2mM SNP (n = 4)

45.04  0.68**

Ca2+ depleted
Double mutant
(Cys49Ser/Cys56Ser)

Single mutant
(Cys49Ser)

Single mutant
(Cys56Ser)

Unmodified/+1mM DTT (n = 3)

37.89  0.51

S-Nitrosylated/+1mM GSNO (n = 6)

37.82  0.43

S-Nitrosylated/+2mM SNP (n = 3)

39.12  0.20

Ca2+ depleted
Unmodified/+1mM DTT (n = 3)

39.04  0.13

S-Nitrosylated/+1mM GSNO (n = 3)

39.05  0.16

Ca2+ depleted
Unmodified/+1mM DTT (n = 4)

38.63  0.19

S-Nitrosylated/+1mM GSNO (n = 4)

38.02  0.47

Statistical analysis was performed using one-way ANOVA followed by Tukey’s test.
*p < 0.05, **p < 0.01 vs. DTT control
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3.3 S-Nitrosylation decreases the structural change of STIM1
23-213 upon Ca2+ binding.
Given that Ca2+ binding affinity drives the sensitivity of the STIM1 luminal domain to
changes in ER/SR Ca2+ levels (Stathopulos et al., 2006), I therefore assessed changes in
Ca2+ binding in the presence and absence of NO. Ca2+ binding was assessed by
monitoring changes in intrinsic fluorescence using 0.1 mg mL-1 wildtype STIM1 23-213
protein in a buffer that contains 20 mM TRIS-HCl (pH 7.4), 150 mM NaCl and 1 mM
DTT or 1 mM GSNO at 37 C. In the absence of the NO donor, the structural change
approached saturation in the ~mM CaCl2 concentration range. Fitting the relative change
in fluorescence intensity to a one-site binding model which takes into account protein
concentration revealed an apparent equilibrium dissociation constant (Kd) for wildtype
STIM1 23-213 in 1 mM DTT of 0.2958  0.0364 mM (mean  SEM, n=3) (Figure 3.4).
This Ca2+ affinity is in the same range of affinities measured previously for STIM1 EFSAM using multiple techniques including changes in intrinsic fluorescence (Stathopulos
et al., 2006). The Kd for the sample in 1 mM GSNO appeared to show a tighter Ca2+
affinity compared to the sample with DTT, with a Kd of 0.0187  0.0162 mM (mean 
SEM, n=3). However, the structural change associated with binding was much smaller,
reflected in the smaller relative change in fluorescence intensity upon addition of
apparently saturating amounts of CaCl2. These Ca2+ binding experiments suggest that the
affinity the STIM1 luminal domain for Ca2+ may be enhanced in the presence of GSNO,
but more compellingly demonstrate that the structural change associated with Ca2+
binding is suppressed in the presence of the NO donor.
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3.4 S-Nitrosylation decreases the level of solvent-exposed
hydrophobicity of wildtype STIM1 23-213.
The Ca2+-depletion-induced oligomerization of STIM1 EF-SAM has previously been
shown to be linked with an increased hydrophobic exposure (Stathopulos et al., 2006).
Thus, I next sought to evaluate the level of hydrophobicity of the STIM1 23-213 luminal
domain in the presence and absence of NO donors using an extrinsic fluorescence probe
(ANS) which binds to surface exposed hydrophobic patches of proteins (Stryer, 1965).
As expected, the extrinsic fluorescence emission of ANS (λex = 372 nm) was higher in
the sample containing 0.143 mg mL-1 of Ca2+-depleted protein compared to buffer alone
(Figure 3.5A). The fluorescence intensity of the buffer, measured from 400 nm to 600
nm, did not change with the addition of 5 mM CaCl2. However, the ANS fluorescence of
the protein sample markedly decreased when 5 mM CaCl2 was added, indicating a
decrease in exposed hydrophobic residues (Figure 3.5A and 3.5C). The right shift in
intensity maximum caused by Ca2+ binding is consistent with increased folding and
higher stability (Figure 3.5A and 3.5C) (Hawe et al., 2008).
In contrast, when evaluating the Ca2+ response of STIM1 23-213 wildtype protein in the
presence 1 mM GSNO (Figure 3.5B), the ANS fluorescence change suggested less
exposed hydrophobicity in the absence of Ca2+ and a smaller conformational change after
the addition of 5 mM CaCl2 due to the persistently well-folded structure of the Snitrosylated protein. Importantly, the STIM1 23-213 Cys49Ser/Cys56Ser double mutant
protein not susceptible to S-nitrosylation (Figure 3.5C) exhibited the same fluorescence
intensity as the wildtype protein (Figure 3.5A); however, even in the presence of excess
GSNO, the STIM1 23-213 Cys49Ser/Cys56Ser double mutant protein showed a higher
fluorescence intensity (Figure 3.5D) compared to the wildtype protein (Figure 3.5B),
indicative of a less compact structure. The slightly lower fluorescence intensity of the
GSNO treated double mutant protein sample (Figure 3.5D) compared to the DTT sample
(Figure 3.5C) may have been caused by a quenching effect (Flaugh and Lumb, 2001;
Tokuriki et al., 2004) exerted by GSNO on ANS fluorescence. This notion is supported
by the absence of a substantial blue shift in intensity maximum for the double mutant
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protein in GSNO buffer (Figure 3.5D) versus the DTT buffer (Figure 3.5C) (~3 nm and 6
nm for Ca2+ depleted and Ca2+ loaded samples respectively), which was found for the
wildtype protein sample (Figure 3.5A and 3.5B) (~26 nm and 23 nm for Ca2+ depleted
and Ca2+ loaded samples respectively). Collectively, the ANS data demonstrated that
STIM1 23-213 undergoes a Ca2+-depletion dependent increase in exposed hydrophobic
surface area which is suppressed in the presence of GSNO, and this suppression of
exposed hydrophobicity is dependent on the presence of Cys49 and Cy56.
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3.5 Wildtype

STIM1

23-213

undergoes

S-nitrosylation

mediated de-oligomerization.
To test whether the effects of S-nitrosylation on hydrophobicity and structure correlate
with oligomerization propensity, I analyzed Ca2+-depleted STIM1 23-213 hydrodynamic
size by DLS. Prior to taking any measurements, the protein and buffer samples were
centrifuged at 12,000 ×g, 4 C for 5 min to remove any aggregates or dust present in the
samples. The control and experimental buffers contained 20 mM TRIS-HCl (pH 7.4), 150
mM NaCl, and 1 mM DTT or 1 mM GSNO, respectively. The autocorrelation functions
were fit to the regularization algorithm to deconvolute the polydisperse distribution of
hydrodynamic sizes, and the percent intensity contribution to the light scattering signal
versus particle radius was assessed as an indication of protein oligomerization. The shift
to the left in the size distribution for the STIM1 23-213 wildtype protein sample which
was exchanged into the GSNO buffer compared to the sample in the DTT buffer
suggested that this luminal region of STIM1 de-oligomerizes following S-nitrosylation
since both samples were first Ca2+ depleted (see Methods section 2.3) (Figure 3.6A). This
is a de-oligomerization event because the protein samples were first stored in a buffer that
contains 1 mM DTT, 20 mM TRIS-HCl (pH 8), 300 mM NaCl and 5 mM CaCl2 and then
subjected prior to the exchange into the DTT control buffer or the GSNO buffer that Snitrosylates the sample. While the change in hydrodynamic size distribution appears
modest, the difference is quite marked when considering that light scattering intensity
scales with particle size to the sixth power (Li et al., 2011). Thus, the hydrodynamic sizes
less than 7 nm contribute greater than 95 % of the light scattering signal in the GSNOtreated sample. This DLS data is consistent with the ANS data showing suppressed
hydrophobicity and the thermal melt measurements demonstrating enhanced stability for
the S-nitrosylated Ca2+ depleted protein. On the other hand, without the S-nitrosylation
sites, the STIM1 23-213 Cys49Ser/Cys56Ser double mutant protein did not undergo deoligomerization after being exchanged into the GSNO experimental buffer (Figure 3.6B).
Taken together, the DLS observations demonstrate that GSNO de-oligomerizes luminal
STIM1 in a Cys49 and Cys56-dependent manner.
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3.6 S-Nitrosylation of STIM1 24-57 peptide causes residue
specific chemical shift changes.
Next, I used solution NMR spectroscopy to probe the structural effects of S-nitrosylation
at higher resolution. The 1H-15N HSQC NMR spectrum of

13

C,

15

N double labelled

STIM1 24-57 protein showed the amide H(N) crosspeaks clustered in the ~7.5-8.5 ppm
region (Figure 3.7). The low peak dispersion clustered in the central region of the 1H-15NHSQC was indicative of an unfolded state (Yao et al., 1997). To ascertain precisely
which residues were being affected by the NO donor GSNO and evaluate any structural
changes associated with the modification(s), a 3D HNCACB spectrum was acquired for
sequential backbone assignment. This approach enabled the assignment of ~85 % of the
C, C, H, N backbone chemical shifts for the STIM1 24-57 fragment in GSNO buffer.
After the protein was exchanged into a buffer containing 2 mM DTT, another set of 1H15

N-HSQC and HNCACB experiments were run. Furthermore, ~84% of the C, C, H,

N backbone chemical shifts were assigned for the peptide in the presence of DTT (Figure
3.7). A comparison of the 1H-15N-HSQCs in the presence of excess GSNO or DTT and
associated assignments revealed numerous chemical shift perturbations (Figure 3.7).
These chemical shift changes suggest residue-specific structural changes associated with
the NO modifications. A subsequent chemical shift perturbation (CSP) map revealed that
the largest chemical shift changes were clustered near the Cys49 and Cys56 residues
(Figure 3.8A and 3.8B), as expected for Cys-specific S-nitrosylation.
With the majority of the backbone chemical shifts assigned, the chemical shift index
(CSI) of the STIM1 24-57 fragment with and without S-nitrosylation of the Cys49 and
Cys56 was then calculated to probe for the possible formation of regular secondary
structure (Hafsa et al., 2015). The CSI showed that, in isolation, this region of STIM1
does not form regular secondary structure either in the S-nitrosylated or in the fully
reduced state. Remarkably, an evaluation of the random coil index (RCI) (Berjanskii and
Wishart, 2005) revealed strikingly higher order parameters (S2) for residues clustered
near the Cys49 site, suggesting a rigidification of this region of STIM1 upon Snitrosylation (Figure 3.9).
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Collectively, these solution NMR data revealed that excess NO donor site-specifically
modifies the Cys49 and Cys56 residues, causes a structural change in the non-conserved
N-terminal fragment and results in a remarkable rigidification of the residues localized
around the Cys49.
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3.7 S-Nitrosylation induces thermodynamic stabilization of
STIM1 23-213.
To more carefully assess how the rigidification of the 24-57 region affected the entire
STIM1 luminal domain stability, I next performed chemical denaturation experiments to
thermodynamically quantify the stability changes caused by S-nitrosylation. Unlike the
thermal denaturation experiments described in section 3.2, the chemical denaturation
process was completely reversible and was thus amenable to equilibrium analyses. Urea
unfolding was monitored by changes in intrinsic fluorescence (λex = 280 nm, λem = 339
nm) at 25 C using 5 μM STIM1 23-213 wildtype or Cys49Ser/Cys56Ser double mutant
protein solubilized in a buffer that contains 20 mM TRIS, 150 mM NaCl and 1 mM DTT
or 1 mM GSNO with or without 5 mM CaCl2. The urea concentrations ranged from 0 to 5
M, while the protein concentration was kept constant at 5 μM. Chemical denaturation
curves (Figure 3.10A-C) were constructed and the thermodynamic stability parameters
such as Gibbs free energy of unfolding in water (ΔGH2O) (Figure 3.10G-I), and the
cooperativity of unfolding (m-value), were extracted via a non-linear regression fitting of
the data to a two state, folded to unfolded model. The urea concentration where half of
the protein macromolecules have unfolded, Cmid (Figure 3.10D-F), was calculated by
dividing ΔGH2O by m (Table 3.2). S-Nitrosylation of STIM1 23-213 wildtype protein by
GSNO under the Ca2+ loaded condition indicated increased protein stability, reflected by
the significant increases in Cmid and ΔGH2O values (Figure 3.10A, D and G). Under the
Ca2+-depleted conditions, this increase in protein stability was even more pronounced
with GSNO treatment compared to the DTT control sample (Figure 3.10B, E and H).
However, for the STIM1 23-213 Cys49Ser/Cys56Ser double mutant protein without the
S-nitrosylation sites, GSNO treatment did not have an effect on the Cmid value (Figure
3.10C and F). In fact, GSNO slightly decreased the ΔGH2O value of the double mutant
protein (Figure 3.10I). Thus, the GSNO-dependent rigidification of the STIM1 24-57
segment endows the full STIM1 luminal domain with enhanced thermodynamic stability
in both the Ca2+-loaded and –depleted states. Further, this thermodynamic stabilization
occurs in a Cys49 and Cys56-specific manner.
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Table 3.2 Thermodynamic stability parameters for STIM1 23-213 wildtype and
Cys49Ser/Cys56Ser double mutant protein under Ca2+-loaded and -depleted conditions.
STIM1 23-213

Treatment

ΔGH2O (25 C)

m-value

Cmid

protein

Condition

(cal mol-1)

(cal mol-1 M-1)

(M)

1 mM DTT
WT
Ca2+ loaded

(n=4)
1 mM GSNO
(n=4)
1 mM DTT

WT

(n=3)

5905 ± 32

1913 ± 65

3.087 ± 0.017

7866 ± 150***

2391 ± 62

3.290 ± 0.063*

1727 ± 9

1297 ± 37

1.331 ± 0.007

3229 ± 58***

1833 ± 63

1.762 ± 0.032***

1746 ± 31

1553 ± 108

1.124 ± 0.020

1450 ± 64*

1275 ± 66

1.145 ± 0.054

Ca2+ depleted
1 mM GSNO
(n=4)
1 mM DTT
Cys49Ser/

(n=3)

Cys56Ser
Ca2+ depleted

1 mM GSNO
(n=3)

ΔGH2O was calculated for using a globally fitted m-value for n=3-4 per group. Statistical
analysis was performed using Student’s unpaired t-test. *p < 0.05 and ***p < 0.0001 vs.
DTT control.
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3.8 STIM1 24-57 peptide transiently interacts with STIM1
58-201 (EF-SAM core) at residues Trp121 and Lys122.
The atomic-resolution structure of the full STIM1 23-213 region which includes the
Cys49 and Cys56 has not been elucidated. Thus, to probe where the STIM1 24-57 may
interact with the core EF-SAM domain and ascertain how enhanced rigidification of 2457 may increase the thermodynamic stability of the entire luminal domain in the presence
of GSNO, I applied a PRE solution NMR spectroscopy approach. An 1H-15N-HSQC EFSAM spectrum was acquired using a 600 μL sample containing 107 μM Cys49 and
Cys56 nitroxide spin-labelled STIM1 24-57 peptide and 46 μM

15

N single-labelled EF-

SAM protein. When the protein mixture was in the NMR buffer containing 20 mM TRIS,
50 mM NaCl and 5 mM CaCl2 (pH 7.4), the region near Trp121Nε1 [side chain indole
N(H)] and Lys122 (backbone amide) on the HSQC spectrum reproducibly showed
significantly lower intensities compared to the HSQC obtained following the addition of
15 mM DTT where the nitroxide spin label was removed from the Cys residues (Figure
3.11, 3.12A and 3.12B). The average intensity ratio (i.e. absence/presence of DTT) of all
N(H) crosspeaks for the protein mixture was near 1, whereas the broadening effect
caused by the nitroxide spin labels on the peptide resulted in a significantly lower
intensity ratio near residues Trp121 and Lys122 in the EF-SAM protein (Figure 3.12C).
Mapping these residue positions on the 3D solution structure of the Ca2+-loaded STIM1
EF-SAM core, revealed these two residues are in the EF-hand domain, spatially near the
N-terminal end of EF-SAM where the unresolved STIM1 24-57 region extends (Figure
3.13). Therefore, these PRE experiments suggested that the 24-57 region interacts with
the EF-SAM core in the EF-hand domain near the Trp121 and Lys122 residues. The 3D
solution structure of EF-SAM core was generated using PYMOL Molecular Graphics
System, Schrödinger, LLC.
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3.9 STIM1 23-213 Trp121Glu/Lys122Glu double mutant does
not de-oligomerize following GSNO treatment.
S-Nitrosyl groups add an electronegative surface potential to the modification sites
(Okamoto et al., 2014). Thus, to validate that the interaction site determined by PRE was
mechanistically relevant to the NO donor-mediated suppressed oligomerization, a STIM1
23-213 Trp121Glu/Lys122Glu double mutant was engineered and assessed by DLS in the
presence and absence of GSNO. I rationalized that the negative charges introduced by the
Trp121Glu/Lys122Glu double mutant would clash with the electronegative surface
potential of the S-nitrosothiol groups and abrogate de-oligomerization by blocking any
increased folding and stability. The oligomerization state of Ca2+-depleted STIM1 23-213
Trp121Glu/Lys122Glu double mutant protein in a buffer that contains 20 mM TRIS, 150
mM NaCl and, 1 mM DTT or 1 mM GSNO (pH 7.4) was assessed via DLS using a
quartz MicroCuvette. At 37 C, under the presence of the NO donor GSNO and
propensity for S-nitrosylation of both Cys49 and Cys56 sites, the wildtype protein deoligomerized compared to the DTT sample, as observed previously (Figure 3.6A).
However, the Trp121Glu/Lys122Glu double mutant protein did not de-oligomerize even
with the GSNO treatment (Figure 3.14). Indeed, this double mutation revealed the
importance of the Trp121 and Lys122 residues in creating an electropositive environment
conducive for complementary charge interactions with the S-nitrosylation sites and
reinforced the notion that these residues were likely the sites where STIM1 24-57
transiently interacted with EF-SAM.
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3.10 STIM1 siRNA and BTP2 blockade of Orai1 channel
activity decreased PE-induced hypertrophy
The Feng laboratory has recently demonstrated that treatment of HEK293 cells coexpressing YFP-Orai1 and mCherry-STIM1 with the NO donor (GSNO) inhibited
STIM1 puncta formation and CRAC current but not in cells co-expressing YFP-Orai1
and the Cys49Ser/Cys56Ser STIM1 double mutant (Gui et al., 2017). To further extend
this work and to complement my in vitro data using the isolated STIM1 luminal domain
fragments, I assessed the cell size of cultured neonatal rat cardiomyocytes treated with 50
μM PE to induce the hypertrophic phenotype with and without STIM1 siRNA or BTP2 as
SOCE inhibitors. As expected, PE treated cells showed significantly enlarged size
compared to untreated controls (Figure 3.15A and 3.15B). However, when the ventricular
cardiomyocytes were transfected with 10 nM STIM1 siRNA 24 h prior to PE treatment or
when 5 μM BTP2 was added concurrently with PE, essentially inhibiting the STIM1 and
Orai1 proteins from the SOCE pathway, respectively, no hypertrophic phenotype was
observed (Figure 3.15A and 3.15B). In the absence of PE treatment, neither the siRNA
nor the BTP2 affected cardiomyocyte size. Thus, these primary culture experiments
demonstrated that SOCE plays a significant role in the development of PE-induced
cardiomyocyte hypertrophy.

3.11 GSNO and adenoviral nNOS inhibits PE-induced
hypertrophy
To test how NO affects cardiomyocyte hypertrophy, I applied a similar cardiomyocyte
size assessment to neonatal rat cardiomyocytes incubated with 100 μM exogenous GSNO
during the administration of PE or cells infected with adenoviral nNOS (moi = 10) 24 h
to enhance NO production prior to PE treatment. The exogenous NO donor GSNO
(Figure 3.16A and 3.16B) or ectopic adenoviral nNOS expression (Figure 3.17A and
3.17B) were both able to inhibit PE-induced neonatal rat cardiomyocyte hypertrophy
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(Figure 3.16 and 3.17). In the absence of PE treatment, neither the GSNO incubation nor
the adenoviral nNOS significantly affected cardiomyocyte size. Taken together, the
previous work from the Feng laboratory and the present cellular cardiomyocyte
experiments demonstrates that NO suppresses cardiomyocyte hypertrophy via a STIM1
and SOCE-dependent manner which involves Cys49 and Cys56 of STIM1.
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Chapter 4

Discussion

4.1 Summary
It has long been known that NO plays a critical role in cardiomyocyte contractility,
excitation-contraction coupling and development of the hypertrophic phenotype (Kelly et
al., 1996). Over-activation of the STIM1-mediated SOCE pathway is often the precursor
for pathological cardiac hypertrophy (Luo et al., 2012). Previous studies have found that
S-glutathionylation of STIM1 at Cys56 decreases its Ca2+ binding affinity and promotes
STIM1 oligomerization, which leads to CRAC channel formation and activation of the
SOCE pathway, independent of the level of ER Ca2+ stores (Hawkins et al., 2010). The
constitutive CRAC channel activation causes sustained Ca2+ level increases and can even
lead to mitochondrial Ca2+ overload mediated apoptosis (Giorgi et al., 2012). This Sglutathionylation effect is opposite to the effect of S-nitrosylation based on my data
described herein. Specifically, my results showed that S-nitrosylation of STIM1 luminal
domain by excess NO donors like GSNO stabilized the domain via a mechanism that
involves rigidification of the non-conserved N-terminal domain and enhanced folding and
stability likely mediated by interactions with the EF-hand domain. These structural and
dynamic changes suppressed both surface exposed hydrophobicity and oligomerization,
biophysical properties that drive homomeric protein-protein interactions and STIM1mediated initiation of SOCE. This work was extended into primary cell culture, where I
demonstrated that cardiomyocytes incubated with GSNO or ectopic nNOS expression
attenuated PE-induced cardiomyocyte hypertrophy. Consistently, knockdown of STIM1
or pharmacologically blocking Orai1 channel activity, also attenuated PE-induced
cardiomyocyte hypertrophy. Collectively, my work suggests that NO can attenuate
STIM1-mediated SOCE, by modification of the N-terminal Cys49 and Cys56 residues
which suppresses the biophysical properties which promote destabilization-coupled
oligomerization of the luminal domain.
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4.2 S-Nitrosylation
S-Nitrosylation is a readily reversible post-translational modification which adds NO
groups onto reduced Cys residues and forms S-nitrosocysteines in different proteins
(Figure 1.3). The S-nitrosylated proteins can subsequently affect the structure and
function of target proteins, thereby amplifying any regulatory effects (Gould et al., 2013;
Haldar and Stamler, 2013; Hess and Stamler, 2012). For instance, a recent study showed
that S-nitrosylation affects the function of Ca2+ handling proteins including cardiac
troponin C, phospholamban and RyR (Irie et al., 2015). This group found that following
β-AR stimulation by an agonist such as isoproterenol, the extent of Ca2+ handling protein
S-nitrosylation is dependent on GSNOR levels, which ultimately regulates cardiomyocyte
function (Irie et al., 2015). In another study, S-nitrosylation of GAPDH at Cys247 was
found to inhibit its ability to appropriately function as a chaperone protein, which led to
the ubiquitination and degradation of ribosomal protein L13a (Jia et al., 2012).
Dysregulated S-nitrosylation or denitrosylation can result in serious pathological
conditions. For instance, the metabolic enzyme GSNOR can selectively reduce the Snitrosothiol group from GSNO or cellular proteins and is tightly regulated in order to
maintain physiological homeostasis and resist nitrosative stress-induced damage.
Dysregulation of arginine metabolic pathways and lack of NO production can also lead to
many pathological conditions including allergic asthmas and sepsis (Carraway et al.,
1998; Maarsingh et al., 2006).
In my investigation, we applied an approach of excess NO donor treatment to promote Snitrosylation of STIM1 residues Cys49 and Cys56, as has been applied previously with
other proteins (Bocedi et al., 2004; Feng et al., 2011; Hao et al., 2004; Liu et al., 2002).
Specific modification at Cys49 and Cys56 by GSNO was confirmed via solution NMR
spectroscopy after assigning the chemical shifts of the short non-conserved luminal
peptide in STIM1 upstream of the EF-SAM domain (i.e. STIM1 24-57). These short,
non-conserved N-terminal regions of STIM1 have been previously shown to influence
EF-SAM stability and affect the activation kinetics of Orai1 channels (Stathopulos et al.,
2009; Zhou et al., 2009). After the sequential backbone assignments were made, the
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maximal chemical shift perturbations caused by GSNO treatment for the Cα and Cβ
carbons as well as the amide hydrogen and nitrogen were centered at the Cys49 and
Cys56. There was also a rigidification around Cys49 following GSNO induced Snitrosylation (Figure 3.9) based on the higher order parameter (S2) predicted from the
RCI (Berjanskii and Wishart, 2005).
Several lines of evidence suggest that S-nitrosylation of Cys49 and Cys56 is the main
modification in my excess GSNO treatment strategy. First, other studies have
successfully S-nitrosylated proteins using this strategy (Bocedi et al., 2004; Feng et al.,
2011; Hao et al., 2004; Liu et al., 2002). Second, Cys49-Cys56 disulfide formation has
been demonstrated to enhance STIM1 activation and SOCE (Prins et al., 2011). Third, Sglutathionylation, a possible modification with the use of GSNO, destabilizes the STIM1
luminal domain and promotes STIM1-mediated activation of SOCE (Stathopulos
laboratory, unpublished data; Hawkins et al., 2010). Fourth, weak NO donors such as
SNAP have no affect on STIM1 23-213 stability (Stathopulos laboratory, unpublished
data). Similarly, I observed a concentration-dependent response in my SNP experiments,
where lower concentrations (i.e. 1 mM) caused less stabilization of STIM1 23-213 than
higher concentrations (i.e. 2 mM). Finally, the Feng laboratory has demonstrated GSNOdependent S-nitrosylation of STIM1 using a biotin switch assay (Forrester et al., 2009;
Gui et al., 2017).

4.3 S-Nitrosylation of luminal STIM1 region increases
protein stability.
The SR Ca2+ sensing luminal region of STIM1 (i.e. STIM1 23-213) becomes activated
under Ca2+ depletion conditions and adopts a destabilized conformation that triggers the
activation of downstream processes in the SOCE pathway (Marshall et al., 2015;
Stathopulos and Ikura, 2010, 2013; Stathopulos et al., 2006; Stathopulos et al., 2013;
Stathopulos et al., 2009; Stathopulos et al., 2008). Therefore, STIM1 stability inversely
correlates with its ability to become activated, where STIM1 stabilization inhibits its
ability to initiate SOCE.
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My work showed that the luminal region of STIM1 has an α-helical structure (Figure
3.1); the level of α-helix is reduced upon Ca2+ depletion. This partial loss in α-helicity is
evident by the reduction in negative ellipticity and is in-line with previous observations
which show a loss in α-helical structure associated with STIM1 activation (Stathopulos et
al., 2006; Stathopulos et al., 2009; Stathopulos et al., 2008; Zheng et al., 2008).
Consistent with this loss in α-helical structure, my thermal stability assessment revealed
Tm values which were markedly reduced in the Ca2+-depleted state for STIM1 23-213.
Remarkably, however, I found that S-nitrosylation by GSNO or SNP under both the Ca2+
loaded and depleted conditions significant increased the apparent Tm values compared to
the Cys-reduced states (Figure 3.2A-D). This elevation in apparent Tm is more
pronounced under Ca2+ depletion conditions, which is the state where STIM1 becomes
activated. In order to ensure that this stabilization effect under the presence of NO donors
GSNO and SNP is indeed due to S-nitrosylation of Cys49 and Cys56 residues in STIM1
luminal region, the STIM1 23-213 Cys49Ser/Cys56Ser double mutant protein was
utilized. Although the double mutation caused an overall destabilization of the protein
compared to WT, the Tm for the double mutant protein was not statistically different with
and without the NO donors (Figure 3.3A and 3.3B), suggesting that the NO induced
stabilization of luminal STIM1 is Cys specific.
Surprisingly, no stabilization was detectable for either Cys49Ser or Cys56Ser single
mutants in the presence of GSNO. This could be due to several reasons. The stabilization
effect by S-nitrosylation on the single mutants could be too small to be detectable in
thermal denaturation experiments. The NO-stabilization effect may also be insufficient to
overcome the single Cys mutation-induced destabilization. Moreover, based on my
results from section 3.8 and 3.9, the interaction between STIM1 24-57 peptide and
residues Trp121 and Lys122 from the EF-hand domain was necessary for S-nitrosylation
to exert an effect. Perhaps this interaction also requires both S-nitrosylation sites to be
present. It should be noted that our laboratory previously demonstrated that the single
Cys49Ser or Cys56Ser mutants significantly decrease SOCE in HEK-293 cells incubated
with GSNO (Gui et al., 2017); thus, the lack of detection of an effect in vitro in my
experiments may have been due to insensitivity of the assays.
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My chemical denaturation experiments enabled the extraction of the thermodynamic
stability parameters, Gibbs free energy of unfolding in water (ΔGH2O) and cooperativity
of unfolding (m-value). S-Nitrosylation of STIM1 23-213 wildtype protein using GSNO
increased the urea concentration at which half of the macromolecules become unfolded
(Cmid) as well as the ΔGH2O value under both the Ca2+ loaded and depleted conditions
(Figure 3.10 A and 3.10B), consistent with my thermal stability observations. Moreover,
without the presence of the S-nitrosylation sites, the STIM1 23-213 Cys49Ser/Cys56Ser
double mutant protein did not exhibit pronounced changes in thermodynamic parameters
(Figure 3.10C and 3.10I).
Since studies have qualitatively suggested both protein stabilizing (Cai et al., 2015; Kohr
et al., 2014; Li et al., 2007; Renganathan et al., 2002; Takahashi et al., 2007) and
destabilizing consequences (Albertos et al., 2015; Kumar et al., 2017; Qu et al., 2007) of
S-nitrosylation, the role of this post-translational modification in folding and stability
appears to be protein specific. Nevertheless, my study is the first to quantify the
thermodynamic stability changes (i.e. GH2O) associated with S-nitrosylation and may
provide a starting point for understanding how the folded to unfolded equilibrium of
proteins can be regulated by NO.

4.4 S-Nitrosylation of luminal STIM1 suppresses Ca2+dependent conformational changes and oligomerization.
The SR Ca2+ sensor STIM1 becomes activated upon Ca2+ depletion (Zhao et al., 2015).
Therefore, the ability for STIM1 to change into an active conformation in response to
changes in luminal Ca2+ concentration is critical for its function. The Ca2+ dissociation
constant (Kd) of the wildtype STIM1 23-213 in 1 mM DTT control is 0.30  0.04 mM
(mean  SEM, n=3). My binding affinity estimate for the STIM1 23-213 protein is in the
same range as determined for the core STIM1 EF-SAM domain previously (Stathopulos
et al., 2006; Zheng et al., 2008). This Kd fits well with the estimated magnitude of
depletion in ER Ca2+ levels (Luik et al., 2008; Luik et al., 2006).
Quantitatively, my Ca2+ binding experiments suggested that GSNO-treated STIM1 23-
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213 has a tighter binding affinity compared to DTT; however, the structural change
associated with Ca2+ binding in the presence of GSNO was only ~1.6 % compared to the
Ca2+ free state. Thus, the Kd value in the presence of treatment with GSNO was not as
reliably determined as the DTT sample which showed ~20 % change in fluorescence
intensity (Figure 3.4). Since the difference in the relative change in fluorescence intensity
is an indicator of the magnitude of structural change associated with the binding, these
binding experiments suggest that the GSNO treated WT protein undergoes a much
smaller structural change upon Ca2+ binding compared to the DTT sample.
The extrinsic fluorescent dye, ANS, was used in my study to characterize these structural
changes further in the presence of DTT or GSNO. ANS acts as a hydrophobic probe and
has frequently been used to measure the exposed surface hydrophobicity of proteins
including ubiquitin C-terminal hydrolase-1 (UCHL1) that is essential in the development
of Parkinson’s disease (Kumar et al., 2017), C-reactive protein (CRP) that is found at
inflammatory sites (Singh et al., 2012) and folate binding protein (FBP) which affects
cell growth and division via its regulation of folic acid (Holm et al., 2012), to name a
few. Specifically, S-nitrosylation of the ubiquitin carboxyl-terminal hydrolase L1
(UCHL1) enzyme at residues Cys90, Cys152 and Cys220 was found to decrease its
structural stability, promote aggregation and catalyze the oligomerization of α-synuclein
which forms Lewy bodies in Parkinson’s patients (Kumar et al., 2017). Under the
presence of excess GSNO, the resultant high ANS fluorescence signal indicates an
increase in UCHL1 exposed hydrophobicity following S-nitrosylation (Kumar et al.,
2017). In my investigation, the ANS fluorescence in the presence of STIM1 23-213
wildtype protein plus GSNO was much lower compared to the DTT control sample, and
the decrease in fluorescence intensity following the addition of 5 mM CaCl2 was also
attenuated for the GSNO experimental sample compared to the DTT control (Figure 3.5A
and 3.5B). On the other hand, the STIM1 23-213 Cys49Ser/Cys56Ser double mutant
protein in GSNO buffer had a much higher ANS fluorescence intensity and change in
fluorescence after CaCl2 treatment compared to the wildtype protein sample (Figure 3.5B
and 3.5D). Consistent with my intrinsic fluorescence Ca2+ binding experiments, these
ANS data show that in the presence of GSNO, STIM1 23-213 undergoes a smaller
structural change than observed with DTT. However, these ANS data also reveal that the
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exposed hydrophobicity in the presence and absence of Ca2+ is reduced in the presence of
GSNO in a Cys-specific manner.
Studies have shown that oligomerization is one of the key mechanisms that activates or
inhibits protein function by influencing their ability to initiate downstream processes
depending on the structure of that particular protein. For instance, oligomerization of
AMP-activated protein kinase (AMPK) heterotrimers leads to its autoinhibition because
the active sites become hidden inside the large inert oligomers following AMPK
aggregation (Scholz et al., 2009). On the other hand, oligomerization of procaspase-9,
caspase-2, caspase-10 or murine caspase-11 can lead to their activation which result in
inflammation and the initiation of apoptosis (Chang et al., 2003). Moreover, Snitrosylation of surfactant protein (SP)-D promotes the formation of trimers instead of
dodecamers or higher order multimers and induces calreticulin/CD91 and p38 MAPK
activation to trigger the pro-inflammatory response (Guo et al., 2008). In this case, SOCE
is initiated upon STIM1 homo-oligomerization in response to SR Ca2+ depletion (Luik et
al., 2008; Stathopulos et al., 2006; Stathopulos et al., 2008). Therefore, the
oligomerization state of STIM1 directly influences the SOCE pathway. Results from my
DLS experiments indicate that STIM1 23-213 wildtype protein de-oligomerizes
following S-nitrosylation by exchanging the protein into a buffer that contains excess
amount of the NO donor GSNO (Figure 3.6A). As a negative control, without the Snitrosylation sites, STIM1 23-213 Cys49Ser/Cys56Ser double mutant protein does not
undergo this de-oligomerization event and has the same apparent particle size distribution
in the presence of both DTT and GSNO (Figure 3.6B). This oligomerization assessment
is consistent with the smaller structural change associated with Ca2+ binding and
decreased exposed hydrophobicity.

4.5 STIM1 24-57 peptide interacts with STIM1 58-201 (EFSAM domain) at residues Trp121 and Lys122 to mediate
S-nitrosylation-induced stabilization of STIM1.
It has been previously shown that S-nitrosylation of methione adenosyltransferase at
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Cys121 inactivates this protein (Perez-Mato et al., 1999). However, the ability for Snitrosylation to occur was greatly reduced by replacing the surrounding charged amino
acids (i.e. acidic Asp355 or basic Arg357 and Arg363) with Ser (Perez-Mato et al.,
1999). Interestingly, it was also found that removal of the NO donor from the isolated rat
hepatocyte incubation medium quickly led to denitrosylation and reactivation of this
protein, demonstrating the reversible nature of this modification (Perez-Mato et al.,
1999). In a more recent study, S-nitrosylation of the cytoplasmic rhodanese domain from
the E. coli membrane-bound sulfurtransferase protein (YgaP) at Cys63 has been found to
enhance the stability of this protein (Eichmann et al., 2016). The structural changes were
examined using NMR, and S-nitrosylation of rhodanese caused the C-terminal helix α5 to
move away from the active site loop (i.e. Cys63-Thr69) due to the reduced charge
interaction between this C-terminal helix and the active site, thus, disrupting the
formation of an unstable conformation of the α5 helix (Eichmann et al., 2016). In my
investigation, I applied a PRE approach to reveal the structural basis for the increased
stability, decreased structural sensitivity to Ca2+ binding, reduction in exposed
hydrophobicity and suppressed oligomerization. My PRE experiments revealed that
STIM1 24-57 peptide transiently interacts with the EF-SAM domain core at residues
Trp121 and Lys122 (Figure 3.11, 3.12 and 3.13). Further, when I introduced a STIM1 23213 Trp121Glu/Lys122Glu double mutant designed based on the PRE observation, the
de-oligomerization following GSNO treatment did not occur (Figure 3.14). Thus, Trp121
and Lys122 may provide a complementary electrostatic environment conducive to
interactions with S-nitrosylated Cys49 and Cys56 residues and suggests an Snitrosylation-mediated regulatory effect whereby S-nitrosylation of Cys49 and Cys56
lead to increased interactions between the 24-57 region and the EF-SAM core, increasing
stability, suppressing hydrophobicity and inhibiting oligomerization, the key initiation
event of SOCE.

4.6 Inhibition

of

the

SOCE

pathway

prevents

the

development of PE-induced cardiomyocyte hypertrophy.
Pathological cardiac hypertrophy can develop in patients that experience chronic stress
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on the heart due to hypertension, MI or genetic sarcomeric protein mutations (Levy et al.,
1988; Seidman and Seidman, 2001). This deleterious hypertrophic condition is
characterized by an enlargement of the heart muscle as a result of increased
cardiomyocyte size (Soonpaa et al., 1996). One of the main signaling mechanisms that
mediate the development of the hypertrophic phenotype is the calcineurin/NFAT pathway
that can become activated in response to sustained elevation of cytosolic Ca2+ levels (Luo
et al., 2012). Following the initial event of PE binding to the PM GPCR (α1-AR), IP3 is
produced by PLC and activates SR IP3R to enable the release of Ca2+ store from the SR.
This Ca2+ depletion in the SR results in STIM1 activation and translocation to the SR-PM
junction as well as Orai1 recruitment and activation into forming CRAC channels. The
entry of Ca2+ from the extracellular space via the CRAC channels maintains cytosolic
Ca2+ elevation, initiates the calcineurin/NFAT pathway and results in the upregulation of
pro-hypertrophic gene signalling (Hogan et al., 2003; Musaro et al., 1999). In my studies,
when the SR Ca2+ sensor STIM1 or CRAC channel subunit Orai1 from the SOCE
pathway is inhibited by STIM1 siRNA or BTP2, respectively, the hypertrophic
phenotype does not develop in primary cultured ventricular cardiomyocytes even in the
presence of the α1-AR agonist PE (Figure 3.15).
In my investigation, primary cultured ventricular cardiomyocytes from neonatal Sprague
Dawley rats were also treated using the exogenous NO donor GSNO along with PE or
adenoviral nNOS prior to the addition of PE. S-Nitrosylation of the Ca2+ sensor STIM1
by GSNO or NO that is produced by nNOS (Gui et al., 2017, in revision) attenuated the
ability of STIM1 to become activated following SR Ca2+ depletion and inhibited the
progression of the SOCE pathway, ultimately preventing the development of PE-induced
cardiomyocyte hypertrophy (Figures 3.16 and 3.17).
Results from previous work in our lab indicate that nNOS deficiency or vinyl-l-N-5-(1imino-3-butenyl)-l-ornithine (L-VNIO) treatment that selectively inhibits nNOS enhances
SOCE and CRAC currents in cardiomyocytes, whereas GSNO inhibits CRAC currents in
nNOS-/- cardiomyocytes (Gui et al., 2017, in revision). These data are fully consistent
with my observations that GSNO or adenoviral nNOS mediated S-nitrosylation of STIM1
inhibits its activation and prevents the development of the hypertrophic phenotype in
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cardiomyocytes. This is also consistent with my data where STIM1 and Orai1 inhibition
by STIM1 siRNA and BTP2, respectively, prevents PE-induced cardiomyocyte
hypertrophy.

4.7 Future directions and limitations
Solution NMR spectroscopy experiments using STIM1 24-57 peptide in a buffer that
contains either GSNO or DTT revealed residue specific chemical shift changes clustering
near Cys49 and Cys56 as well as rigidification near Cys49 following S-nitrosylation.
Although the structure of the STIM1 24-57 peptide that contains the S-nitrosylation sites
was characterized in the present study, structures of the S-nitrosylated and de-nitrosylated
STIM1 23-213 states which encompass both the short luminal peptide and EF-SAM
domain will provide further insights into structural perturbations and changes associated
with Cys49 and Cys56 S-nitrosylation in the full luminal domain context.
There are two human STIM homologues, STIM1 and STIM2, which are highly similar in
sequence and domain architecture (Figure 1.2) (Hooper et al., 2013). Human STIM1 is a
SR Ca2+ sensor that becomes activated following Ca2+ depletion and mediates the
activation of Orai1 into forming functional CRAC channels in the SOCE pathway,
whereas the homologous STIM2 functions as a main regulator of basal Ca2+ homeostasis
(Brandman et al., 2007). Although STIM2 activation is also dependent on stored Ca2+
levels, it has a weaker Ca2+ binding affinity and becomes activated when the stores are
near full (Gruszczynska-Biegala et al., 2011; Stathopulos et al., 2013; Zheng et al., 2008;
Zheng et al., 2011). STIM2 also has the two Cys residues in the luminal region available
to be S-nitrosylated, so understanding how S-nitrosylation affects the biophysical
properties, structure and function of STIM2 will provide valuable information on the
mechanisms of basal Ca2+ homeostasis. Further, the N-terminal region (other than the
Cys49 and Cys56) is dissimilar between STIM2 and STIM1, and so precisely how or if
these differences are involved in the mechanisms of S-nitrosylation regulation remain to
be determined.
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Thus far, the effects of S-nitrosylation on PE-induced hypertrophy have only been
investigated using neonatal Sprague-Dawley rat primary cell cultures. Moreover, Snitrosylation of STIM1 was induced by treating the cells in selective wells with GSNO or
adenoviral nNOS. Therefore, in vivo studies using STIM1 Cys49Ser/Cys56Ser transgenic
mice would enable us to evaluate the effect of Cys49- and Cys56-specific S-nitrosylation
in the larger scale physiological context.
There are limitations associated with the present study. First, aside from residues Cys49
and Cys56 in the luminal region of STIM1 under investigation, there are other Cys
residues that may be S-nitrosylated, including Cys227 in the TM domain and Cys437 in
the cytosolic CAD region. Moreover, all of my experiments were performed under the
presence of excess NO donors GSNO or SNP due to the labile nature of the protein
modification by S-nitrosylation which limited the types of investigations conducted. For
instance, Ca2+ binding experiments were not performed using CD spectroscopy due to the
pronounced elevation in high tension associated with the GSNO and SNP buffers. Direct
measurement of S-nitrosylation by mass spectroscopy was unsuccessful due to the labile
nature of this modification. The unstable modification also made it challenging to
estimate the level of S-nitrosylated protein in ventricular cardiomyocytes. In vitro, the
level of S-nitrosylated protein could not be estimated which prevented the assessment of
whether both Cys49 and Cys56 residues were similarly susceptible to this modification.

4.8 Conclusions
Protein post-translational modifications including S-nitrosylation, phosphorylation,
ubiquitination, acetylation, palmitoylation, sumoylation and redox modifications, to name
a few, have been recognized as critical modulators of cell signaling, regulating the
biophysical, biochemical and structural properties of myriad cellular proteins (Hess and
Stamler, 2012). The modification under investigation, S-nitrosylation, is a reversible Cys
modification that adds NO groups onto the SH sidechain of reduced Cys residues (Figure
1.3) which ultimately affects the structure and function of the S-nitrosylated target
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protein. Understanding the thermodynamic consequences of S-nitrosylation and
mechanisms by which S-nitrosylation of the SR Ca2+ sensor STIM1 contributes to Ca2+
signaling enhances our comprehension of CRAC channel mediated SOCE. Collectively,
my data revealed that S-nitrosylation of residues Cys49 and Cys56 in the luminal domain
stabilizes and inhibits STIM1 activation by promoting a more compact protein
conformation with less exposed hydrophobicity and less propensity for oligomerization
(Table 4.1). Moreover, my thermodynamic data quantifies the energetic effects of Cys49
and Cys56 S-nitrosylation on the luminal domain of STIM1.
In the full-length STIM1 context, my data suggests that S-nitrosylation of STIM1
prevents the Ca2+-depletion dependent oligomerization and translocation of STIM1. This
inhibition would preclude the recruitment and activation of Orai1 into forming functional
CRAC channels at the ER-PM junctions. Ultimately, the lack of sustained cytosolic Ca2+
elevation mediated by CRAC would prevent calcineurin/NFAT pathway signaling and
the development of the hypertrophic phenotype (Figure 4.1). Consistent with my model
of STIM1 regulation by NO (Figure 4.1) SOCE inhibition at the level of STIM1 or Orai1
using STIM1 siRNA and BTP2 respectively, as well as inhibition of STIM1 activation by
S-nitrosylation using GSNO or adenoviral nNOS prevents the development of PEinduced cardiomyocyte hypertrophy. NO has long been known to confer cardiovascular
benefits by relaxing narrowed blood vessels, increasing oxygen and blood flow
(Forstermann et al., 1994). However, my research demonstrates that NO may also play a
role in preventing cardiac hypertrophy by inhibiting STIM1 activation.

Table 4.1. Summary of the effect of S-nitrosylation on various properties associated with
STIM1 activation.
-S-Ha
Thermal stabilityb

-S-N=Oa
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Structural change
following Ca2+ bindingb
Exposed hydrophobicityb
Oligomerizationb
Thermodynamic stabilityb
Cardiomyocyte
hypertrophyc
relatively lower
a

properties of unmodified (-S-H) relative to S-nitrosylated (-S-N=O) STIM1

b

c

relatively higher

experiments performed using recombinant human STIM1 23-213 protein

experiments performed using neonatal rat cardiomyocytes with endogenous STIM1
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